nifedipine has been researched along with Hypertension, Pulmonary in 265 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
Hypertension, Pulmonary: Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was designed to determine whether calcium antagonists, diltiazem and nifedipine, can depress low temperature-induced pulmonary hypertension (PH) in broilers (also known as ascites) and to characterize their efficacy on hemodynamics and pulmonary artery function." | 9.14 | Calcium antagonists, diltiazem and nifedipine, protect broilers against low temperature-induced pulmonary hypertension and pulmonary vascular remodeling. ( Gao, M; Guo, Y; Qiao, J; Yang, Y, 2010) |
| " Long-term therapy with aerosolized iloprost (long-acting PGI(2) analog) resulted in unequivocal clinical improvement from a state of immobilization and severe resting dyspnea in a patient with decompensated right heart failure." | 9.09 | Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. ( Ghofrani, HA; Grimminger, F; Olschewski, H; Schermuly, R; Seeger, W; Temmesfeld-Wollbruck, B; Walmrath, D, 1999) |
| "The clinical course in primary pulmonary hypertension (PPH) is improved by calcium channel blocker therapy in those with a favorable hemodynamic response during a trial of high-dose oral nifedipine." | 9.09 | Echocardiographic predictors of an adverse response to a nifedipine trial in primary pulmonary hypertension: diminished left ventricular size and leftward ventricular septal bowing. ( Armstrong, WF; Bach, DS; Bossone, E; Ricciardi, MJ; Rubenfire, M, 1999) |
| "The objective of this study was to evaluate the long-term results of an 18 months nifedipine treatment in patients with pulmonary hypertension (PHT) secondary to chronic obstructive broncho-pulmonary disease (COBPD)." | 9.06 | [Long-term treatment of pulmonary hypertension in chronic obstructive bronchopneumopathies with nifedipine. Hemodynamic study over 18 months]. ( Arnaud, A; Philip-Joet, F; Saadjian, A; Vestri, R, 1989) |
| "A two-year-old child dying of pulmonary hypertension and cor pulmonale secondary to bronchopulmonary dysplasia, was demonstrated to have reactive pulmonary hypertension in response to 100% oxygen and isoproterenol infusion." | 9.06 | Treatment of pulmonary hypertension with diltiazem in a child with bronchopulmonary dysplasia. ( Bingham, WT; Duncan, WJ; Kasian, GF; Mersal, A; Ninan, A; Sankaran, K; Tyrrell, MJ, 1988) |
| "Meta-analysis of the trials of nifedipine therapy in patients with pulmonary hypertension demonstrated a decrease in pulmonary artery pressure that was associated with an amelioration of clinical symptoms." | 8.79 | Meta-analysis of the long-term effect of nifedipine for pulmonary hypertension. ( Lehrman, S; Malik, AS; Warshafsky, S, 1997) |
| "We have studied the prophylactic administration of nifedipine and its molecular mechanism involved in reducing the transvascular leakage and inflammation in rats under hypoxia." | 7.78 | Nifedipine inhibits hypoxia induced transvascular leakage through down regulation of NFkB. ( M, C; Mathew, T; P, H; S K S, S; S, S, 2012) |
| " The aim of the present study was to explore the effects of CPU0213, a dual endothelin ET(A)/ET(B) receptor antagonist, and nifedipine, a calcium antagonist, in relieving pulmonary hypertension (PH)." | 7.75 | CPU0213, a non-selective ETA/ETB receptor antagonist, improves pulmonary arteriolar remodeling of monocrotaline-induced pulmonary hypertension in rats. ( Cheng, YS; Cui, B; Dai, DZ; Dai, Y; Li, N; Zhang, TT, 2009) |
| "The effects of inhaled nitric oxide (NO) on hemodynamics and right ventricular (RV) contractility were compared with those of nitroprusside and nifedipine in 14 patients with severe chronic pulmonary hypertension." | 7.71 | Comparison of the effects of nitric oxide, nitroprusside, and nifedipine on hemodynamics and right ventricular contractility in patients with chronic pulmonary hypertension. ( Bigatello, LM; Cockrill, BA; Fifer, MA; Ginns, LC; Kacmarek, RM; Semigran, MJ; Zapol, WM, 2001) |
| "Acute hemodynamic effects of beraprost sodium were tested in a canine vasoconstrictive pulmonary hypertension model induced by the continuous infusion of U-46619, a thromboxane A(2)mimetic." | 7.71 | Comparative effects of beraprost, a stable analogue of prostacyclin, with PGE(1), nitroglycerin and nifedipine on canine model of vasoconstrictive pulmonary hypertension. ( Kurumatani, H; Matsushita, T; Tamura, M, 2001) |
| "In a young woman with primary pulmonary hypertension, treatment with low-dose nifedipine resulted in resolution of symptoms and of tricuspid regurgitation." | 7.70 | Rapid recurrence of pulmonary hypertension following cessation of nifedipine. ( Fennell, WH; Gallagher, MM; Hart, CM; Vaughan, CJ, 1998) |
| "The purpose of this study was to assess the utility of inhaled nitric oxide (NO), a selective pulmonary vasodilator, for predicting the safety and acute hemodynamic response to high-dose oral nifedipine in primary pulmonary hypertension (PPH)." | 7.70 | Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine. ( Knight, BP; Martinez, FJ; Ricciardi, MJ; Rubenfire, M, 1998) |
| " We wanted to determine whether nifedipine treatment prevents the increased pulmonary vascular resistance, blunted pulmonary vascular responses to acetylcholine, and reduced lung endothelial nitric oxide synthase (eNOS) amounts that we have found in a newborn model of chronic hypoxia-induced pulmonary hypertension." | 7.70 | Nifedipine inhibits pulmonary hypertension but does not prevent decreased lung eNOS in hypoxic newborn pigs. ( Fike, CD; Kaplowitz, MR, 1999) |
| "Experiments were carried on rats to study the preventive effects of calcium channel blockers Nitrendipine, Nifedipine and L-Arginine (L- Arginine is the physiological precursor of nitric oxide in endothelium-dependent relaxation) on chronic intermittent hypoxia induced pulmonary hypertension, on the right ventricular hypertrophy and pulmonary vascular pathologic changes." | 7.69 | [Comparative effects of calcium channel blockers and L-arginine on chronic intermittent hypoxic pulmonary hypertension in rats]. ( Chen, SC; Li, MR; Ma, G, 1994) |
| "In patients with primary pulmonary hypertension who respond to nifedipine during acute drug testing, there is a significant linear correlation of serum nifedipine concentration with pulmonary artery pressure and resistance." | 7.69 | Serum nifedipine concentrations and response of patients with pulmonary hypertension. ( Bauman, JL; Hoon, TJ; Phillips, BG; Rich, S; Schoen, MD; Schrader, BJ, 1996) |
| "Calcium channel blockers and adenosine have each been shown to be effective in reducing pulmonary artery pressure and pulmonary vascular resistance in patients with primary pulmonary hypertension." | 7.68 | Effects of adenosine in combination with calcium channel blockers in patients with primary pulmonary hypertension. ( Inbar, S; Kaufmann, E; Rich, S; Schrader, BJ; Vestal, RE, 1993) |
| "The present study was undertaken to evaluate at rest the short- and long-term effects of oral nifedipine (N) in patients with pulmonary hypertension (PH)." | 7.68 | Short- and long-term hemodynamic effects of oral nifedipine in patients with pulmonary hypertension secondary to COPD and lung fibrosis. Deleterious effects in patients with restrictive disease. ( Domenighetti, GM; Saglini, VG, 1992) |
| "The hemodynamic effects of intravenously administered adenosine, a potent vasodilator, were examined in 15 patients with pulmonary hypertension." | 7.68 | Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. ( Inbar, S; Kaufmann, L; Rich, S; Schrader, BJ; Vestal, RE, 1992) |
| "We report the successful use of nifedipine in the treatment of acute pulmonary hypertension in an infant after a cardiac operation." | 7.68 | Successful treatment of acute postoperative pulmonary hypertension with nifedipine. ( Davis, DA; Russo, P, 1992) |
| "Ten patients with pulmonary hypertension associated with diffuse systemic sclerosis (1 patient), the CREST syndrome (calcinosis cutis, Reynaud's phenomenon, esophageal dysmotility, sclerodactyl, telangiectasia) (6 patients) and mixed connective tissue disease (3 patients) were studied to assess the effect of oral nifedipine on pulmonary and systemic hemodynamics." | 7.68 | Acute and long-term effects of nifedipine on pulmonary and systemic hemodynamics in patients with pulmonary hypertension associated with diffuse systemic sclerosis, the CREST syndrome and mixed connective tissue disease. ( Alpert, MA; Lambert, CR; Mukerji, B; Mukerji, V; Panayiotou, H; Pressly, TA; Sharp, GC, 1991) |
| "A 34-year-old man with primary pulmonary hypertension developed acute nonhemodynamic pulmonary edema after a loading dose of nifedipine." | 7.68 | Acute nonhemodynamic pulmonary edema with nifedipine in primary pulmonary hypertension. ( Decroly, P; Gottignies, P; Prigogine, T; Verhoeven, A; Waterlot, Y, 1991) |
| "To observe acute hemodynamic effects of pulmonary hypertension in chronic obstructive lung disease by nifedipine, we studied 16 patients with pulsed doppler ultrasound." | 7.68 | [Pulsed Doppler echocardiography assessment of acute hemodynamic effects of nifedipine on pulmonary hypertension in chronic obstructive lung disease]. ( Yuan, H, 1991) |
| "The pharmacokinetics and associated pharmacodynamics of nifedipine were studied in nine children aged 5 to 68 mo with bronchopulmonary dysplasia and pulmonary artery hypertension after a single oral dose of 1." | 7.68 | Pharmacokinetics and pharmacodynamics of nifedipine in children with bronchopulmonary dysplasia and pulmonary hypertension. ( Amidon, GL; Beekman, RH; Johnson, CE; Kostyshak, DA; Nguyen, T; Oh, DM, 1991) |
| "We evaluated the effects of the calcium channel blocker nifedipine (Nf) as a vasodilator compared with oxygen administration on pulmonary hypertension and right ventricular performance in 15 patients with COPD." | 7.68 | [Effects of nifedipine on pulmonary hypertension in patients with chronic obstructive pulmonary diseases--a comparison with oxygen administration]. ( Liu, Z; Yu, RJ, 1991) |
| "The effects of nifedipine in a single dose of 10 mg on the pulmonary circulation and the selected right and left ventricular function indices were studied in a group of 10 patients with secondary pulmonary hypertension (mean systolic pressure 55." | 7.68 | [Comparative study of acute and chronic effects of nifedipine in patients with secondary pulmonary hypertension]. ( Dubiel, JP; Królikowski, T; Mazurek, S; Nikodemowicz, M; Zmudka, K, 1991) |
| " Nifedipine depressed Qt significantly in this glass-bead embolization model of acute pulmonary hypertension." | 7.68 | Hemodynamic profiles of prostaglandin E1, isoproterenol, prostacyclin, and nifedipine in experimental porcine pulmonary hypertension. ( McLean, R; Pearl, RG; Prielipp, RC; Rosenthal, MH, 1991) |
| "The acute hemodynamic effects of both sublingual nifedipine (N) and intravenous hydralazine (Hy) were studied in 5 patients with primary pulmonary hypertension to ascertain whether the capacity for pulmonary vasodilatation was generalized or drug-specific, and to determine which of the 2 agents had preferential pulmonary vasodilatory effects." | 7.67 | Hemodynamic effects of nifedipine versus hydralazine in primary pulmonary hypertension. ( Borer, JS; Fisher, J; Goldberg, HL; Mermelstein, M; Moses, JW; Niarchos, AP; Whitman, HH, 1984) |
| "Two women with primary pulmonary hypertension were treated with felodipine, a vasodilating agent." | 7.67 | Felodipine in primary pulmonary hypertension. Report of two cases. ( Arnman, K; Rydén, L; Smedgård, P; Thorhallsson, E, 1984) |
| "The potential short-term pulmonary vasodilator effect of a calcium-channel blocker, nifedipine, was tested in seven patients with primary pulmonary hypertension." | 7.67 | Hemodynamic effects of nifedipine at rest and during exercise in primary pulmonary hypertension. ( Cohn, JN; Levine, TB; Olivari, MT; Weir, EK, 1984) |
| "A 23-year-old female with moderate primary pulmonary hypertension (PPH) was treated by chronic oral administration of long-acting prostaglandin-E1 (PGE1) and nifedipine." | 7.67 | [A case of primary pulmonary hypertension with beneficial effect of oral long-acting prostaglandin E1 and nifedipine]. ( Nagao, I; Ogawa, K; Oida, A; Tsukada, K; Yoshimura, M, 1989) |
| "The hemodynamic effects of nifedipine in 15 patients with pulmonary hypertension (PH) secondary to congenital heart disease (CHD) were evaluated." | 7.67 | [Therapeutic effects of nifedipine in pulmonary hypertension secondary to congenital heart disease]. ( Bai, YR; Chen, H; Wang, SZ, 1989) |
| "The acute effects of oxygen, nifedipine, and diltiazem were studied in eight patients with cystic fibrosis and mild pulmonary hypertension, to assess the possibility of relieving the latter before the occurrence of irreversible vascular changes." | 7.67 | Acute effects of oxygen, nifedipine, and diltiazem in patients with cystic fibrosis and mild pulmonary hypertension. ( Bossuyt, A; Dab, I; Davidson, A, 1989) |
| "The case of a 55-year-old woman with primary pulmonary hypertension is described who developed 2 hours after sublingual administration of a 10 mg capsule of nifedipine a severe rise in pulmonary arterial and right atrial pressures accompanied with dyspnoea and cyanosis." | 7.67 | Paradoxical elevation of pulmonary vascular resistance after nifedipine in primary pulmonary hypertension. A case study. ( Grad, A; Horvat, M; Mozina, M; Pohar, B; Rakovec, P, 1989) |
| "We evaluated in patients suffering from COPD-related pulmonary hypertension whether nifedipine therapy lowers acutely and chronically pulmonary vascular pressure and resistance and whether pulmonary transmural pressure may be further lowered by the combined use of nifedipine and oxygen." | 7.67 | Nifedipine reduces pulmonary pressure and vascular tone during short- but not long-term treatment of pulmonary hypertension in patients with chronic obstructive pulmonary disease. ( Agostoni, P; Doria, E; Galli, C; Guazzi, MD; Tamborini, G, 1989) |
| "We designed experiments to determine whether intermittent hypoxia would produce significant pathologic and physiologic changes in rats and whether pretreatment with a calcium channel blocker, nitrendipine, would reduce the pulmonary vascular remodeling and right ventricular hypertrophy caused by intermittent hypoxia." | 7.67 | Nitrendipine attenuates the pulmonary vascular remodeling and right ventricular hypertrophy caused by intermittent hypoxia in rats. ( Buescher, P; de la Monte, SM; Farrukh, I; Gottlieb, J; Gurtner, G; Hutchins, GM; Kennedy, TP; Lodato, R; Michael, JR; Rock, PC, 1986) |
| "Cardiovascular responses to the calcium antagonist nifedipine, alone and combined with low dose acetylsalicyclic acid (ASA), were evaluated in a piglet model of endotoxin-induced pulmonary hypertension." | 7.67 | The effect of nifedipine alone or combined with low dose acetylsalicyclic acid on endotoxin-induced pulmonary hypertension in the piglet. ( Huth, RG; Jüngst, BK; Schranz, D; Stopfkuchen, H, 1988) |
| "The effects of a single dose of nifedipine (20 mg sublingual) on the haemodynamics and parameters of tissue oxygenation were assessed by right heart catheterisation and oximetry of mixed arterial and venous blood in 24 patients with pulmonary hypertension secondary to severe chronic obstructive airways disease." | 7.67 | [Nifedipine in the treatment of chronic cor pulmonale]. ( Arnaud, A; Philip-Joet, F; Saadjian, A; Torresani, J; Tran N'guyen, A, 1986) |
| "In 41 patients with chronic obstructive pulmonary disease (COPD) and pulmonary hypertension, the effects of sublingual administration of 20 mg nifedipine and 0." | 7.67 | [Vasodilator therapy in pulmonary hypertension and chronic obstructive lung disease (COPD). Hemodynamic studies exemplified by nifedipine and nitroglycerin]. ( Fridrich, L; Gassner, A; Klicpera, M; Magometschnigg, D; Sommer, G, 1986) |
| "The acute hemodynamic effects of nifedipine were evaluated and compared to the effects of 95% oxygen in six children with bronchopulmonary dysplasia and pulmonary artery hypertension." | 7.67 | Acute hemodynamic effects of nifedipine in infants with bronchopulmonary dysplasia and pulmonary hypertension. ( Beekman, RH; Brownlee, JR; Rosenthal, A, 1988) |
| "To determine whether Nifedipine reduces pulmonary artery pressure and pulmonary vascular resistance in patients with hypoxic pulmonary hypertension, we have studied ten clinically stable patients with chronic obstructive airways disease following acute administration of sublingual Nifedipine 20 mg and also after three months long term treatment with Nifedipine tablets 20mg bd." | 7.67 | Acute and long term effect of nifedipine on pulmonary hypertension secondary to chronic obstructive airways disease. ( Cunnington, AR; Johnson, DC; Joshi, RC; Mehta, R, 1986) |
| "The effects of a single dose of nifedipine (20 mg sublingually) on hemodynamics and tissue oxygenation were evaluated in 24 patients suffering from pulmonary hypertension secondary to severe chronic obstructive lung disease." | 7.67 | Hemodynamic and oxygen delivery responses to nifedipine in pulmonary hypertension secondary to chronic obstructive lung disease. ( Arnaud, A; Philip-Joet, F; Saadjian, A, 1987) |
| "To detect whether pulmonary vascular responsiveness is a factor which can aggravate the pulmonary hypertension induced by irreversible pulmonary fibrosis, we examined the acute hemodynamic effects of low-flow oxygen and of nifedipine both at rest and during exercise in 8 patients with idiopathic pulmonary fibrosis (IPF)." | 7.67 | Pulmonary vascular responsiveness at rest and during exercise in idiopathic pulmonary fibrosis: effects of oxygen and nifedipine. ( Galavotti, V; Gunella, G; Papiris, S; Sturani, C, 1986) |
| "The favourable effect of long-term (36 months) treatment with nifedipine in a case of primary pulmonary hypertension is described." | 7.67 | Long-term favourable effect of nifedipine in primary pulmonary hypertension. Report of a case with hemodynamic evaluation after 3 and after 16 months and with clinical follow-up during 36 months. ( Di Donato, M; Musante, R, 1985) |
| "We evaluated the hemodynamic effects of the calcium antagonist nifedipine in 13 consecutive patients admitted to the intensive care unit with secondary pulmonary hypertension." | 7.67 | Hemodynamic effects of nifedipine on secondary pulmonary hypertension in man. ( Carlier, J; Cremers, S; D'Orio, V; el Allaf, D; Garzaniti, N; Marcelle, R, 1985) |
| "In 10 patients with advanced chronic lung disease and pulmonary hypertension central haemodynamics and pulmonary gas exchange were studied at rest and during exercise, before and during continuous infusion of the calcium antagonist felodipine, which lowers vascular resistance by selective action on vascular smooth muscle." | 7.67 | The effect of a new calcium antagonist, felodipine, on pulmonary hypertension and gas exchange in chronic obstructive lung disease. ( Bratel, T; Hedenstierna, G; Nyquist, O; Ripe, E, 1985) |
| "The effects of nifedipine on hemodynamics and blood gases were studied in 10 patients with pulmonary hypertension secondary to chronic obstructive lung disease." | 7.67 | Two-week nifedipine treatment for pulmonary hypertension complicating chronic obstructive lung disease. ( Arnaud, A; Guintoli, A; Philip-Joet, F; Saadjian, A; Torresani, J, 1985) |
| "A 64-year-old woman with systemic sclerosis and pulmonary hypertension underwent Swan-Ganz catheterization to test her response to the calcium channel blocker nifedipine." | 7.67 | Transient effect of nifedipine on pulmonary hypertension of systemic sclerosis. ( Fudman, EJ; Kelling, DG, 1985) |
| "To evaluate the potential value of nifedipine treatment for primary pulmonary hypertension, hemodynamic and scintigraphic measurements were made before and 15 to 30 minutes after nifedipine, 10 to 20 mg, was given sublingually to nine patients." | 7.66 | Treatment of primary pulmonary hypertension with nifedipine. A hemodynamic and scintigraphic evaluation. ( Firth, BG; Hillis, LD; Nicod, P; Rubin, LJ, 1983) |
| "The effects of 3 types of vasoactive agents, hydralazine, nifedipine and amrinone, were evaluated in 7 patients with primary pulmonary hypertension (PPH)." | 7.66 | Comparative actions of hydralazine, nifedipine and amrinone in primary pulmonary hypertension. ( Ganz, R; Levy, PS; Rich, S, 1983) |
| "The effect of sublingual nifedipine (20 mg) on haemodynamics at rest and during bicycle ergometry in supine position was assessed in 22 patients with precapillary pulmonary hypertension (obstructive form: n = 17, restrictive form: n = 2, combined obstructive-restrictive: n = 3)." | 7.66 | [Effect of nifedipine on hemodynamics in precapillary pulmonary hypertension at rest and during exertion]. ( Fridrich, L; Gassner, A; Lenz, K; Pichler, M; Sykora, J; Tizek, H, 1983) |
| "The effects of nifedipine on hemodynamics and pulmonary gas exchange were investigated in two patients with primary pulmonary hypertension." | 7.66 | Effects of nifedipine on ventilation/perfusion matching in primary pulmonary hypertension. ( Denolin, H; Mélot, C; Mols, P; Naeije, R; Vandenbossche, JL, 1983) |
| "Progressive dyspnea and syncope occurred in a young woman with primary pulmonary hypertension despite therapy with hydralazine." | 7.66 | Hemodynamic effects of nifedipine in primary pulmonary hypertension. ( Douglas, JS, 1983) |
| "In a 22-year-old woman with primary pulmonary hypertension resistant to all previous attempts to reduce the pulmonary vascular resistance, there was dramatic improvement after the first dose of nifedipine, 20 mg po, which was not sustained with subsequent doses." | 7.66 | Rapid attenuation of response to nifedipine in primary pulmonary hypertension. ( Fennell, WH; Luck, JC; Tortoledo, F; Wood, BA, 1982) |
| "The advantages of long-term administration of vasodilators in the treatment of chronic cor pulmonale were investigated after informed consent in 60 patients with obstructive respiratory insufficiency (56 men, 4 women, mean age 63." | 6.66 | One-year clinical study on nifedipine in the treatment of pulmonary hypertension in chronic obstructive lung disease. ( Arnaud, A; Philip-Joet, F; Saadjian, A; Surpas, P; Vestri, R, 1988) |
| "Myocyte apoptosis and muscle atrophy were significantly decreased with irbesartan compared with untreated CHF rats." | 5.31 | Beneficial effects on skeletal muscle of the angiotensin II type 1 receptor blocker irbesartan in experimental heart failure. ( Angelini, A; Battista Ambrosio, G; Dalla Libera, L; Ravara, B; Rossini, K; Sandri, M; Thiene, G; Vescovo, G, 2001) |
| "Nifedipine was administered in 20 mg doses hourly during right cardiac catheterization and was repeated after 1 hour until a decrease in systemic pressure occurred." | 5.29 | [Effect of large doses of nifedipine on pulmonary hypertension in patients with recurrent pulmonary thromboembolism]. ( Fijałkowska, A; Filipecki, S; Hajduk, B; Pałasiewicz, G; Polowiec, Z; Radomyski, A; Tomkowski, W, 1994) |
| "Nifedipine (10 mg/kg) was administered intraperitoneally every day." | 5.29 | The effect of nifedipine on monocrotaline-induced pulmonary hypertension in rats. ( Harada, Y; Inoue, M; Mori, C; Tanaka, O; Watanabe, K, 1993) |
| "Nifedipine was discontinued after 8 months due to lack of improvement in the patient's state." | 5.28 | [Treatment of primary pulmonary hypertension with high doses of nifedipine controlled by Doppler echocardiography]. ( Filipecki, S; Pasierski, T; Radomyski, A; Tomkowski, W; Torbicki, A, 1991) |
| " Under this aspect we examined 44 patients by right heart catheterisation at rest and at exercise before and after sublingual application of a single dose of 20 mg nifedipine (Corinfar) as well as under continuous dosage of 30-60 mg daily." | 5.28 | The influence of nifedipine (Corinfar) on pulmonary hypertension in chronic obstructive lung disease. ( Evers, H; Harzbecker, K; Orschekowski, H; Schauer, J; Schilling, W; Steiniger, L; Winkler, J, 1990) |
| "Pulmonary hypertension was produced by continuous intravenous administration of U46619 to halothane-anesthetized sheep." | 5.28 | Hemodynamic effects of diltiazem during vasoconstrictor pulmonary hypertension in sheep. ( Finn, JC; Pearl, RG, 1990) |
| "Nifedipine was found to be the most effective." | 5.28 | [A case of primary pulmonary hypertension with high venous thromboxane B2 concentration]. ( Abe, S; Kawakami, Y; Kishi, F; Miyamoto, K; Nagata, H; Nakano, T; Suzuki, A; Takahashi, S; Takai, S, 1990) |
| " During 12 weeks of prednisone treatment in a dosage of 40 mg daily, her condition markedly deteriorated clinically and hemodynamically as manifested by pulmonary artery pressure (PAP), pulmonary vascular resistance (PVR), cardiac output (CO), mixed venous O2 saturation, and systemic vascular resistance (SVR)." | 5.28 | Nifedipine and prazosin in the management of pulmonary hypertension in CREST syndrome. ( Dresner-Feigin, R; Galun, E; Glikson, M; Pollack, A; Rubinow, A, 1990) |
| "Primary pulmonary hypertension is a disease of unknown etiology." | 5.28 | [Nifedipine in primary pulmonary hypertension while waiting for heart-lung transplantation]. ( Petersen, TI; Svanegård, J; Thayssen, P, 1989) |
| "Nifedipine was then administered sublingually in a dose of 1 mg/kg and produced an immediate and dramatic improvement in the right radial artery pO2 that was sustained despite persistence of the right-to-left shunt." | 5.28 | [Efficacy of nifedipine on refractory hypoxemia associated with diaphragmatic hernia in the newborn infant. Apropos of a case]. ( Burguet, A; Destuynder, R; Fromentin, C; Menget, A, 1989) |
| "Nifedipine is a calcium antagonistic drug which reduces elevated vascular resistances." | 5.26 | Hemodynamic effects of nifedipine in pulmonary hypertension. ( Camerini, F; Fioretti, P; Klugmann, S; Salvi, A, 1982) |
| "This study was designed to determine whether calcium antagonists, diltiazem and nifedipine, can depress low temperature-induced pulmonary hypertension (PH) in broilers (also known as ascites) and to characterize their efficacy on hemodynamics and pulmonary artery function." | 5.14 | Calcium antagonists, diltiazem and nifedipine, protect broilers against low temperature-induced pulmonary hypertension and pulmonary vascular remodeling. ( Gao, M; Guo, Y; Qiao, J; Yang, Y, 2010) |
| " Long-term therapy with aerosolized iloprost (long-acting PGI(2) analog) resulted in unequivocal clinical improvement from a state of immobilization and severe resting dyspnea in a patient with decompensated right heart failure." | 5.09 | Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. ( Ghofrani, HA; Grimminger, F; Olschewski, H; Schermuly, R; Seeger, W; Temmesfeld-Wollbruck, B; Walmrath, D, 1999) |
| "The clinical course in primary pulmonary hypertension (PPH) is improved by calcium channel blocker therapy in those with a favorable hemodynamic response during a trial of high-dose oral nifedipine." | 5.09 | Echocardiographic predictors of an adverse response to a nifedipine trial in primary pulmonary hypertension: diminished left ventricular size and leftward ventricular septal bowing. ( Armstrong, WF; Bach, DS; Bossone, E; Ricciardi, MJ; Rubenfire, M, 1999) |
| "To assess changes in physiologic shunting and oxygenation following short-term treatment with nifedipine in patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease." | 5.07 | Effect of nifedipine on physiologic shunting and oxygenation in chronic obstructive pulmonary disease. ( Bone, MF; Kalra, L, 1993) |
| "Detailed examination of hemodynamics in patients with portal and pulmonary hypertension was performed upon acute drug tests and course administration of nitrosorbide++, corinfar and propranolol." | 5.07 | [Drug therapy of pulmonary and portal hypertension in liver cirrhosis]. ( Andreev, NG; Maev, IV; Vorob'ev, LP, 1991) |
| "The objective of this study was to evaluate the long-term results of an 18 months nifedipine treatment in patients with pulmonary hypertension (PHT) secondary to chronic obstructive broncho-pulmonary disease (COBPD)." | 5.06 | [Long-term treatment of pulmonary hypertension in chronic obstructive bronchopneumopathies with nifedipine. Hemodynamic study over 18 months]. ( Arnaud, A; Philip-Joet, F; Saadjian, A; Vestri, R, 1989) |
| "A two-year-old child dying of pulmonary hypertension and cor pulmonale secondary to bronchopulmonary dysplasia, was demonstrated to have reactive pulmonary hypertension in response to 100% oxygen and isoproterenol infusion." | 5.06 | Treatment of pulmonary hypertension with diltiazem in a child with bronchopulmonary dysplasia. ( Bingham, WT; Duncan, WJ; Kasian, GF; Mersal, A; Ninan, A; Sankaran, K; Tyrrell, MJ, 1988) |
| " A patient is described who had POEMS syndrome with precapillary pulmonary hypertension and Raynaud's phenomenon, and who responded well to a short course of corticosteroids and long term nifedipine." | 4.80 | Reversible pulmonary hypertension in POEMS syndrome--another etiology of triggered pulmonary vasculopathy? ( Bossone, E; Erba, H; Paciocco, G; Rubenfire, M, 2000) |
| "Meta-analysis of the trials of nifedipine therapy in patients with pulmonary hypertension demonstrated a decrease in pulmonary artery pressure that was associated with an amelioration of clinical symptoms." | 4.79 | Meta-analysis of the long-term effect of nifedipine for pulmonary hypertension. ( Lehrman, S; Malik, AS; Warshafsky, S, 1997) |
| " Verapamil is extremely effective in patients with supraventricular tachyarrhythmias, hypertrophic cardiomyopathy, and the various anginal syndromes, but it appears to be ineffective or possibly even deleterious in those with pulmonary hypertension, congestive heart failure of any cause, and Raynaud's phenomenon or disease." | 4.77 | Calcium antagonists in patients with cardiovascular disease. Current perspectives. ( Hillis, LD; Winniford, MD, 1985) |
| " Biochemical evidence suggests that pulmonary vasoconstriction results from the transmembrane flux of calcium into vascular smooth muscle; accordingly, the pulmonary pressor responses in experimental hypoxic pulmonary hypertension can be attenuated by verapamil and nifedipine." | 4.77 | Therapeutic application of calcium-channel antagonists for pulmonary hypertension. ( Packer, M, 1985) |
| "The dihydropyridine derivatives increase [Ca(2+)](cyt) by potentiating the activity of CaSR in PASMC independently of their blocking (or activating) effect on Ca(2+) channels; therefore, it is possible that the use of dihydropyridine Ca(2+) channel blockers (eg, nifedipine) to treat IPAH patients with upregulated CaSR in PASMC may exacerbate pulmonary hypertension." | 3.79 | Dihydropyridine Ca(2+) channel blockers increase cytosolic [Ca(2+)] by activating Ca(2+)-sensing receptors in pulmonary arterial smooth muscle cells. ( Guo, Q; Ko, EA; Makino, A; Pohl, NM; Smith, KA; Song, S; Wan, J; Yamamura, A; Yamamura, H; Yuan, JX; Zeifman, A; Zimnicka, AM, 2013) |
| "We have studied the prophylactic administration of nifedipine and its molecular mechanism involved in reducing the transvascular leakage and inflammation in rats under hypoxia." | 3.78 | Nifedipine inhibits hypoxia induced transvascular leakage through down regulation of NFkB. ( M, C; Mathew, T; P, H; S K S, S; S, S, 2012) |
| " The aim of the present study was to explore the effects of CPU0213, a dual endothelin ET(A)/ET(B) receptor antagonist, and nifedipine, a calcium antagonist, in relieving pulmonary hypertension (PH)." | 3.75 | CPU0213, a non-selective ETA/ETB receptor antagonist, improves pulmonary arteriolar remodeling of monocrotaline-induced pulmonary hypertension in rats. ( Cheng, YS; Cui, B; Dai, DZ; Dai, Y; Li, N; Zhang, TT, 2009) |
| " Male Sprague-dawley Rats (220 +/- 20 G) Were Divided Into Four Groups: (I) Control; (Ii) Untreated Hypoxic (28 Days Hypoxia); (Iii) Hypoxic Rats Treated In The Last 5 Days Of Hypoxia With Nifedipine(5 Mg/kg Per Day, P." | 3.73 | CPU0507, an endothelin receptor antagonist, improves rat hypoxic pulmonary artery hypertension and constriction in vivo and in vitro. ( Dai, DZ; Dai, Y; Guan, L; Ji, M; Yuan, SH, 2006) |
| "Both of aminophylline and nifedipine can attenuate pulmonary hypertension in patients with HAPE, but the effect of aminophylline was better than the effect of nifedipine." | 3.72 | [Hemodynamic effects of aminophylline and nifedipine in patients with high altitude pulmonary edema]. ( Cheng, GL; Gao, YQ; Li, SZ; Liou, FY; Mou, XB; Tang, HY; Ye, GL; Zhou, XB, 2004) |
| "The effects of inhaled nitric oxide (NO) on hemodynamics and right ventricular (RV) contractility were compared with those of nitroprusside and nifedipine in 14 patients with severe chronic pulmonary hypertension." | 3.71 | Comparison of the effects of nitric oxide, nitroprusside, and nifedipine on hemodynamics and right ventricular contractility in patients with chronic pulmonary hypertension. ( Bigatello, LM; Cockrill, BA; Fifer, MA; Ginns, LC; Kacmarek, RM; Semigran, MJ; Zapol, WM, 2001) |
| "Acute hemodynamic effects of beraprost sodium were tested in a canine vasoconstrictive pulmonary hypertension model induced by the continuous infusion of U-46619, a thromboxane A(2)mimetic." | 3.71 | Comparative effects of beraprost, a stable analogue of prostacyclin, with PGE(1), nitroglycerin and nifedipine on canine model of vasoconstrictive pulmonary hypertension. ( Kurumatani, H; Matsushita, T; Tamura, M, 2001) |
| "In a young woman with primary pulmonary hypertension, treatment with low-dose nifedipine resulted in resolution of symptoms and of tricuspid regurgitation." | 3.70 | Rapid recurrence of pulmonary hypertension following cessation of nifedipine. ( Fennell, WH; Gallagher, MM; Hart, CM; Vaughan, CJ, 1998) |
| "The purpose of this study was to assess the utility of inhaled nitric oxide (NO), a selective pulmonary vasodilator, for predicting the safety and acute hemodynamic response to high-dose oral nifedipine in primary pulmonary hypertension (PPH)." | 3.70 | Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine. ( Knight, BP; Martinez, FJ; Ricciardi, MJ; Rubenfire, M, 1998) |
| "To describe the clinical course of pregnancies complicated by pulmonary hypertension and treated with the pulmonary vasodilators nifedipine and prostacyclin." | 3.70 | Pulmonary hypertension in pregnancy: treatment with pulmonary vasodilators. ( Easterling, TR; Ralph, DD; Schmucker, BC, 1999) |
| " We wanted to determine whether nifedipine treatment prevents the increased pulmonary vascular resistance, blunted pulmonary vascular responses to acetylcholine, and reduced lung endothelial nitric oxide synthase (eNOS) amounts that we have found in a newborn model of chronic hypoxia-induced pulmonary hypertension." | 3.70 | Nifedipine inhibits pulmonary hypertension but does not prevent decreased lung eNOS in hypoxic newborn pigs. ( Fike, CD; Kaplowitz, MR, 1999) |
| " Rats were exposed to 3 wk of normoxia, hypoxia (10% O2), or monocrotaline (MCT; single dose = 60 mg/kg) and treated with either nothing (control), inhaled NO (20 ppm), or nifedipine (10 mg x kg(-1) x day(-1)." | 3.70 | Inhaled nitric oxide and nifedipine have similar effects on lung cGMP levels in rats. ( Frank, DU; Horstman, DJ; McCall, DA; Rich, GF, 1999) |
| " infusion of U46619, a thromboxane A2 (TXA2) mimic, or by alveolar hypoxia." | 3.69 | HA1004, an intracellular calcium antagonist, selectively attenuates pulmonary hypertension in newborn lambs. ( Crowley, MR; Fineman, JR; Soifer, SJ, 1994) |
| "Experiments were carried on rats to study the preventive effects of calcium channel blockers Nitrendipine, Nifedipine and L-Arginine (L- Arginine is the physiological precursor of nitric oxide in endothelium-dependent relaxation) on chronic intermittent hypoxia induced pulmonary hypertension, on the right ventricular hypertrophy and pulmonary vascular pathologic changes." | 3.69 | [Comparative effects of calcium channel blockers and L-arginine on chronic intermittent hypoxic pulmonary hypertension in rats]. ( Chen, SC; Li, MR; Ma, G, 1994) |
| "In patients with primary pulmonary hypertension who respond to nifedipine during acute drug testing, there is a significant linear correlation of serum nifedipine concentration with pulmonary artery pressure and resistance." | 3.69 | Serum nifedipine concentrations and response of patients with pulmonary hypertension. ( Bauman, JL; Hoon, TJ; Phillips, BG; Rich, S; Schoen, MD; Schrader, BJ, 1996) |
| "NO inhalation can accurately predict a vasodilator response to nifedipine in patients with severe pulmonary hypertension without adverse effects on systemic haemodynamics and gas exchange." | 3.69 | Nitric oxide and prostacyclin as test agents of vasoreactivity in severe precapillary pulmonary hypertension: predictive ability and consequences on haemodynamics and gas exchange. ( Bulpa, P; Chevrolet, JC; Jolliet, P; Ritz, M; Thorens, JB, 1997) |
| "Calcium channel blockers and adenosine have each been shown to be effective in reducing pulmonary artery pressure and pulmonary vascular resistance in patients with primary pulmonary hypertension." | 3.68 | Effects of adenosine in combination with calcium channel blockers in patients with primary pulmonary hypertension. ( Inbar, S; Kaufmann, E; Rich, S; Schrader, BJ; Vestal, RE, 1993) |
| "The present study was undertaken to evaluate at rest the short- and long-term effects of oral nifedipine (N) in patients with pulmonary hypertension (PH)." | 3.68 | Short- and long-term hemodynamic effects of oral nifedipine in patients with pulmonary hypertension secondary to COPD and lung fibrosis. Deleterious effects in patients with restrictive disease. ( Domenighetti, GM; Saglini, VG, 1992) |
| "The hemodynamic effects of intravenously administered adenosine, a potent vasodilator, were examined in 15 patients with pulmonary hypertension." | 3.68 | Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. ( Inbar, S; Kaufmann, L; Rich, S; Schrader, BJ; Vestal, RE, 1992) |
| "We report the successful use of nifedipine in the treatment of acute pulmonary hypertension in an infant after a cardiac operation." | 3.68 | Successful treatment of acute postoperative pulmonary hypertension with nifedipine. ( Davis, DA; Russo, P, 1992) |
| "Ten patients with pulmonary hypertension associated with diffuse systemic sclerosis (1 patient), the CREST syndrome (calcinosis cutis, Reynaud's phenomenon, esophageal dysmotility, sclerodactyl, telangiectasia) (6 patients) and mixed connective tissue disease (3 patients) were studied to assess the effect of oral nifedipine on pulmonary and systemic hemodynamics." | 3.68 | Acute and long-term effects of nifedipine on pulmonary and systemic hemodynamics in patients with pulmonary hypertension associated with diffuse systemic sclerosis, the CREST syndrome and mixed connective tissue disease. ( Alpert, MA; Lambert, CR; Mukerji, B; Mukerji, V; Panayiotou, H; Pressly, TA; Sharp, GC, 1991) |
| "A 34-year-old man with primary pulmonary hypertension developed acute nonhemodynamic pulmonary edema after a loading dose of nifedipine." | 3.68 | Acute nonhemodynamic pulmonary edema with nifedipine in primary pulmonary hypertension. ( Decroly, P; Gottignies, P; Prigogine, T; Verhoeven, A; Waterlot, Y, 1991) |
| "To observe acute hemodynamic effects of pulmonary hypertension in chronic obstructive lung disease by nifedipine, we studied 16 patients with pulsed doppler ultrasound." | 3.68 | [Pulsed Doppler echocardiography assessment of acute hemodynamic effects of nifedipine on pulmonary hypertension in chronic obstructive lung disease]. ( Yuan, H, 1991) |
| "The pharmacokinetics and associated pharmacodynamics of nifedipine were studied in nine children aged 5 to 68 mo with bronchopulmonary dysplasia and pulmonary artery hypertension after a single oral dose of 1." | 3.68 | Pharmacokinetics and pharmacodynamics of nifedipine in children with bronchopulmonary dysplasia and pulmonary hypertension. ( Amidon, GL; Beekman, RH; Johnson, CE; Kostyshak, DA; Nguyen, T; Oh, DM, 1991) |
| "We evaluated the effects of the calcium channel blocker nifedipine (Nf) as a vasodilator compared with oxygen administration on pulmonary hypertension and right ventricular performance in 15 patients with COPD." | 3.68 | [Effects of nifedipine on pulmonary hypertension in patients with chronic obstructive pulmonary diseases--a comparison with oxygen administration]. ( Liu, Z; Yu, RJ, 1991) |
| "Forty-seven patients with primary pulmonary hypertension were evaluated with a dose titration protocol utilizing nifedipine (20 mg orally) or diltiazem (60 mg orally) given every hour until maximal effectiveness was achieved." | 3.68 | High dose titration of calcium channel blocking agents for primary pulmonary hypertension: guidelines for short-term drug testing. ( Kaufmann, E; Rich, S, 1991) |
| "The effects of nifedipine in a single dose of 10 mg on the pulmonary circulation and the selected right and left ventricular function indices were studied in a group of 10 patients with secondary pulmonary hypertension (mean systolic pressure 55." | 3.68 | [Comparative study of acute and chronic effects of nifedipine in patients with secondary pulmonary hypertension]. ( Dubiel, JP; Królikowski, T; Mazurek, S; Nikodemowicz, M; Zmudka, K, 1991) |
| " Nifedipine depressed Qt significantly in this glass-bead embolization model of acute pulmonary hypertension." | 3.68 | Hemodynamic profiles of prostaglandin E1, isoproterenol, prostacyclin, and nifedipine in experimental porcine pulmonary hypertension. ( McLean, R; Pearl, RG; Prielipp, RC; Rosenthal, MH, 1991) |
| "The acute hemodynamic effects of both sublingual nifedipine (N) and intravenous hydralazine (Hy) were studied in 5 patients with primary pulmonary hypertension to ascertain whether the capacity for pulmonary vasodilatation was generalized or drug-specific, and to determine which of the 2 agents had preferential pulmonary vasodilatory effects." | 3.67 | Hemodynamic effects of nifedipine versus hydralazine in primary pulmonary hypertension. ( Borer, JS; Fisher, J; Goldberg, HL; Mermelstein, M; Moses, JW; Niarchos, AP; Whitman, HH, 1984) |
| "The hemodynamic and clinical responses to calcium channel blockade with verapamil and nifedipine were compared with those of hydralazine in 12 patients with pulmonary hypertension secondary to obliterative pulmonary vascular disease." | 3.67 | Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease. ( Medina, N; Packer, M; Yushak, M, 1984) |
| "Cardiovascular responses to the calcium antagonists verapamil and nifedipine were evaluated in a piglet model of hypoxic pulmonary hypertension." | 3.67 | The effect of calcium antagonists on hypoxic pulmonary hypertension in the piglet. ( Bancalari, E; Dickstein, PJ; Goldberg, RN; Trindade, O, 1984) |
| "To determine whether nifedipine reduces pulmonary artery pressure and pulmonary vascular resistance index during rest and exercise in patients with hypoxic pulmonary hypertension, we studied 6 clinically stable patients using a randomized, double-blind, crossover design." | 3.67 | Nifedipine inhibits hypoxic pulmonary vasoconstriction during rest and exercise in patients with chronic obstructive pulmonary disease. A controlled double-blind study. ( Huang, CK; Kallman, CH; Kennedy, TP; Michael, JR; Schlott, W; Summer, W; Zahka, K, 1984) |
| "Two women with primary pulmonary hypertension were treated with felodipine, a vasodilating agent." | 3.67 | Felodipine in primary pulmonary hypertension. Report of two cases. ( Arnman, K; Rydén, L; Smedgård, P; Thorhallsson, E, 1984) |
| "The potential short-term pulmonary vasodilator effect of a calcium-channel blocker, nifedipine, was tested in seven patients with primary pulmonary hypertension." | 3.67 | Hemodynamic effects of nifedipine at rest and during exercise in primary pulmonary hypertension. ( Cohn, JN; Levine, TB; Olivari, MT; Weir, EK, 1984) |
| "Catheterization of the pulmonary artery and radiocirculography were used in 30 patients with chronic bronchitis (CB) in order to study changes in hemodynamics induced by intravenous injections of 5 and 10 mg verapamil or by 4-5 weeks of the treatment with finoptin and corinfar." | 3.67 | [The effect of calcium antagonists on pulmonary hemodynamics in patients with chronic bronchitis with manifest and latent pulmonary hypertension]. ( Volkova, LI, 1989) |
| "A 23-year-old female with moderate primary pulmonary hypertension (PPH) was treated by chronic oral administration of long-acting prostaglandin-E1 (PGE1) and nifedipine." | 3.67 | [A case of primary pulmonary hypertension with beneficial effect of oral long-acting prostaglandin E1 and nifedipine]. ( Nagao, I; Ogawa, K; Oida, A; Tsukada, K; Yoshimura, M, 1989) |
| "The hemodynamic effects of nifedipine in 15 patients with pulmonary hypertension (PH) secondary to congenital heart disease (CHD) were evaluated." | 3.67 | [Therapeutic effects of nifedipine in pulmonary hypertension secondary to congenital heart disease]. ( Bai, YR; Chen, H; Wang, SZ, 1989) |
| "The acute effects of oxygen, nifedipine, and diltiazem were studied in eight patients with cystic fibrosis and mild pulmonary hypertension, to assess the possibility of relieving the latter before the occurrence of irreversible vascular changes." | 3.67 | Acute effects of oxygen, nifedipine, and diltiazem in patients with cystic fibrosis and mild pulmonary hypertension. ( Bossuyt, A; Dab, I; Davidson, A, 1989) |
| "We studied the simultaneous effects of nifedipine on the pulmonary circulation and blood gases in 12 patients with pulmonary hypertension secondary to obstructive chronic bronchitis." | 3.67 | [Value of nifedipine in respiratory failure related to obstructive chronic bronchitis during treatment over 6 months]. ( Boita, F; Boutaud, P; Herpin, D; Ingrand, P; Meurice, JC; Patte, F; Underner, M, 1989) |
| "The case of a 55-year-old woman with primary pulmonary hypertension is described who developed 2 hours after sublingual administration of a 10 mg capsule of nifedipine a severe rise in pulmonary arterial and right atrial pressures accompanied with dyspnoea and cyanosis." | 3.67 | Paradoxical elevation of pulmonary vascular resistance after nifedipine in primary pulmonary hypertension. A case study. ( Grad, A; Horvat, M; Mozina, M; Pohar, B; Rakovec, P, 1989) |
| "To evaluate pulmonary vasoreactivity in children and young adults with primary pulmonary hypertension, we performed cardiac catheterizations on nine patients with primary pulmonary hypertension (nine months to 23 years old) and made hemodynamic measurements: before and after infusing prostacyclin, and before and after administering sublingual nifedipine." | 3.67 | Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension. ( Barst, RJ, 1986) |
| "We evaluated in patients suffering from COPD-related pulmonary hypertension whether nifedipine therapy lowers acutely and chronically pulmonary vascular pressure and resistance and whether pulmonary transmural pressure may be further lowered by the combined use of nifedipine and oxygen." | 3.67 | Nifedipine reduces pulmonary pressure and vascular tone during short- but not long-term treatment of pulmonary hypertension in patients with chronic obstructive pulmonary disease. ( Agostoni, P; Doria, E; Galli, C; Guazzi, MD; Tamborini, G, 1989) |
| "We designed experiments to determine whether intermittent hypoxia would produce significant pathologic and physiologic changes in rats and whether pretreatment with a calcium channel blocker, nitrendipine, would reduce the pulmonary vascular remodeling and right ventricular hypertrophy caused by intermittent hypoxia." | 3.67 | Nitrendipine attenuates the pulmonary vascular remodeling and right ventricular hypertrophy caused by intermittent hypoxia in rats. ( Buescher, P; de la Monte, SM; Farrukh, I; Gottlieb, J; Gurtner, G; Hutchins, GM; Kennedy, TP; Lodato, R; Michael, JR; Rock, PC, 1986) |
| "Cardiovascular responses to the calcium antagonist nifedipine, alone and combined with low dose acetylsalicyclic acid (ASA), were evaluated in a piglet model of endotoxin-induced pulmonary hypertension." | 3.67 | The effect of nifedipine alone or combined with low dose acetylsalicyclic acid on endotoxin-induced pulmonary hypertension in the piglet. ( Huth, RG; Jüngst, BK; Schranz, D; Stopfkuchen, H, 1988) |
| "The effects of a single dose of nifedipine (20 mg sublingual) on the haemodynamics and parameters of tissue oxygenation were assessed by right heart catheterisation and oximetry of mixed arterial and venous blood in 24 patients with pulmonary hypertension secondary to severe chronic obstructive airways disease." | 3.67 | [Nifedipine in the treatment of chronic cor pulmonale]. ( Arnaud, A; Philip-Joet, F; Saadjian, A; Torresani, J; Tran N'guyen, A, 1986) |
| "In 41 patients with chronic obstructive pulmonary disease (COPD) and pulmonary hypertension, the effects of sublingual administration of 20 mg nifedipine and 0." | 3.67 | [Vasodilator therapy in pulmonary hypertension and chronic obstructive lung disease (COPD). Hemodynamic studies exemplified by nifedipine and nitroglycerin]. ( Fridrich, L; Gassner, A; Klicpera, M; Magometschnigg, D; Sommer, G, 1986) |
| "The acute hemodynamic effects of nifedipine were evaluated and compared to the effects of 95% oxygen in six children with bronchopulmonary dysplasia and pulmonary artery hypertension." | 3.67 | Acute hemodynamic effects of nifedipine in infants with bronchopulmonary dysplasia and pulmonary hypertension. ( Beekman, RH; Brownlee, JR; Rosenthal, A, 1988) |
| " Cardiac catheterization revealed a primary pulmonary hypertension sensible to nifedipine, but after the initial favourable results the clinical course rapidly went down and the child died from right sided congestive heart failure." | 3.67 | Unexplained plexogenic pulmonary arteriopathy: an unusual rapidly progressive case in childhood. ( Ammirati, A; Coli, A; Dina, MA, 1988) |
| "The haemodynamic effects of nifedipine were studied in 14 patients (aged 8-14 years, seven male and seven female) with ventricular septal defect with and without pulmonary hypertension." | 3.67 | Acute haemodynamic effects of nifedipine in patients with ventricular septal defect. ( Berisha, S; Frasheri, A; Goda, A; Kastrati, A; Popa, Y, 1988) |
| "To determine whether Nifedipine reduces pulmonary artery pressure and pulmonary vascular resistance in patients with hypoxic pulmonary hypertension, we have studied ten clinically stable patients with chronic obstructive airways disease following acute administration of sublingual Nifedipine 20 mg and also after three months long term treatment with Nifedipine tablets 20mg bd." | 3.67 | Acute and long term effect of nifedipine on pulmonary hypertension secondary to chronic obstructive airways disease. ( Cunnington, AR; Johnson, DC; Joshi, RC; Mehta, R, 1986) |
| " We evaluated the acute and chronic (three months) effects of the thromboxane synthetase inhibitor CGS13080 administered 200 mg every six hours on the resting hemodynamics in ten patients with primary pulmonary hypertension (PPH), and on their response to 20 mg of nifedipine given sublingually before and after the thromboxane synthetase inhibitor treatment." | 3.67 | Thromboxane synthetase inhibition in primary pulmonary hypertension. ( Brundage, BH; Hart, K; Kieras, K; Rich, S, 1987) |
| "The effects of a single dose of nifedipine (20 mg sublingually) on hemodynamics and tissue oxygenation were evaluated in 24 patients suffering from pulmonary hypertension secondary to severe chronic obstructive lung disease." | 3.67 | Hemodynamic and oxygen delivery responses to nifedipine in pulmonary hypertension secondary to chronic obstructive lung disease. ( Arnaud, A; Philip-Joet, F; Saadjian, A, 1987) |
| "We used an improved noninvasive radionuclide method, recently developed by us, to evaluate changes in pulmonary artery pressure induced by sublingual nifedipine in patients with chronic obstructive pulmonary disease and pulmonary hypertension." | 3.67 | The value of right atrial emptying rate in predicting reduction in pulmonary artery pressure in patients with chronic obstructive pulmonary disease. ( Frankel, A; Marmor, AT; Michaeli, S; Plich, M; Schneeweiss, A, 1987) |
| "We studied (via acute vasodilator testing with nifedipine) 27 patients with pulmonary arterial hypertension (PAH) (11 primary, 16 secondary PAH, [including six patients with Raynaud's phenomenon]) in order to identify predictors of hemodynamic response and specifically to assess whether patients with Raynaud's phenomenon and pulmonary hypertension were more likely to respond to nifedipine." | 3.67 | Nifedipine in pulmonary arterial hypertension. Importance of Raynaud's phenomenon. ( Borer, JS; Fisher, J; Likier, HM; Mack, RJ; Schiff, AN, 1987) |
| "To detect whether pulmonary vascular responsiveness is a factor which can aggravate the pulmonary hypertension induced by irreversible pulmonary fibrosis, we examined the acute hemodynamic effects of low-flow oxygen and of nifedipine both at rest and during exercise in 8 patients with idiopathic pulmonary fibrosis (IPF)." | 3.67 | Pulmonary vascular responsiveness at rest and during exercise in idiopathic pulmonary fibrosis: effects of oxygen and nifedipine. ( Galavotti, V; Gunella, G; Papiris, S; Sturani, C, 1986) |
| "The favourable effect of long-term (36 months) treatment with nifedipine in a case of primary pulmonary hypertension is described." | 3.67 | Long-term favourable effect of nifedipine in primary pulmonary hypertension. Report of a case with hemodynamic evaluation after 3 and after 16 months and with clinical follow-up during 36 months. ( Di Donato, M; Musante, R, 1985) |
| "We evaluated the hemodynamic effects of the calcium antagonist nifedipine in 13 consecutive patients admitted to the intensive care unit with secondary pulmonary hypertension." | 3.67 | Hemodynamic effects of nifedipine on secondary pulmonary hypertension in man. ( Carlier, J; Cremers, S; D'Orio, V; el Allaf, D; Garzaniti, N; Marcelle, R, 1985) |
| "In 10 patients with advanced chronic lung disease and pulmonary hypertension central haemodynamics and pulmonary gas exchange were studied at rest and during exercise, before and during continuous infusion of the calcium antagonist felodipine, which lowers vascular resistance by selective action on vascular smooth muscle." | 3.67 | The effect of a new calcium antagonist, felodipine, on pulmonary hypertension and gas exchange in chronic obstructive lung disease. ( Bratel, T; Hedenstierna, G; Nyquist, O; Ripe, E, 1985) |
| "The effects of nifedipine on hemodynamics and blood gases were studied in 10 patients with pulmonary hypertension secondary to chronic obstructive lung disease." | 3.67 | Two-week nifedipine treatment for pulmonary hypertension complicating chronic obstructive lung disease. ( Arnaud, A; Guintoli, A; Philip-Joet, F; Saadjian, A; Torresani, J, 1985) |
| "A 64-year-old woman with systemic sclerosis and pulmonary hypertension underwent Swan-Ganz catheterization to test her response to the calcium channel blocker nifedipine." | 3.67 | Transient effect of nifedipine on pulmonary hypertension of systemic sclerosis. ( Fudman, EJ; Kelling, DG, 1985) |
| "To evaluate the potential value of nifedipine treatment for primary pulmonary hypertension, hemodynamic and scintigraphic measurements were made before and 15 to 30 minutes after nifedipine, 10 to 20 mg, was given sublingually to nine patients." | 3.66 | Treatment of primary pulmonary hypertension with nifedipine. A hemodynamic and scintigraphic evaluation. ( Firth, BG; Hillis, LD; Nicod, P; Rubin, LJ, 1983) |
| "The effects of 3 types of vasoactive agents, hydralazine, nifedipine and amrinone, were evaluated in 7 patients with primary pulmonary hypertension (PPH)." | 3.66 | Comparative actions of hydralazine, nifedipine and amrinone in primary pulmonary hypertension. ( Ganz, R; Levy, PS; Rich, S, 1983) |
| "The effect of sublingual nifedipine (20 mg) on haemodynamics at rest and during bicycle ergometry in supine position was assessed in 22 patients with precapillary pulmonary hypertension (obstructive form: n = 17, restrictive form: n = 2, combined obstructive-restrictive: n = 3)." | 3.66 | [Effect of nifedipine on hemodynamics in precapillary pulmonary hypertension at rest and during exertion]. ( Fridrich, L; Gassner, A; Lenz, K; Pichler, M; Sykora, J; Tizek, H, 1983) |
| "The effects of nifedipine on hemodynamics and pulmonary gas exchange were investigated in two patients with primary pulmonary hypertension." | 3.66 | Effects of nifedipine on ventilation/perfusion matching in primary pulmonary hypertension. ( Denolin, H; Mélot, C; Mols, P; Naeije, R; Vandenbossche, JL, 1983) |
| "Clinical experience with calcium antagonists in congestive heart failure has, to date, been mainly restricted to the use of nifedipine but there is either no or only a limited extent of information available on diltiazem and verapamil." | 3.66 | Calcium antagonists in heart failure. ( Camerini, F; Klugmann, S; Salvi, A, 1983) |
| "Progressive dyspnea and syncope occurred in a young woman with primary pulmonary hypertension despite therapy with hydralazine." | 3.66 | Hemodynamic effects of nifedipine in primary pulmonary hypertension. ( Douglas, JS, 1983) |
| "In a 22-year-old woman with primary pulmonary hypertension resistant to all previous attempts to reduce the pulmonary vascular resistance, there was dramatic improvement after the first dose of nifedipine, 20 mg po, which was not sustained with subsequent doses." | 3.66 | Rapid attenuation of response to nifedipine in primary pulmonary hypertension. ( Fennell, WH; Luck, JC; Tortoledo, F; Wood, BA, 1982) |
| "Thirty-three COPD patients (II = 12, ID = 11, DD = 10) with placebo or nifedipine (10 mg) underwent right heart catheterization with exercise, and systemic and pulmonary haemodynamic variables were examined." | 2.71 | Acute effects of nifedipine administration in pulmonary haemodynamics and oxygen delivery during exercise in patients with chronic obstructive pulmonary disease: implication of the angiotensin-converting enzyme gene polymorphisms. ( Kanazawa, H; Tateishi, Y; Yoshikawa, J, 2004) |
| "Almitrine infusion was followed by an increase in PaO2 (20%) and PVR (48%)." | 2.67 | Nifedipine inhibits the effects of almitrine in patients suffering from pulmonary artery hypertension secondary to chronic obstructive pulmonary disease. ( Arnaud, A; Barret, A; Levy, S; Philip-Joët, F; Saadjian, A, 1993) |
| "High altitude pulmonary edema (HAPE) is characterized by marked pulmonary hypertension." | 2.67 | Prevention and treatment of high altitude pulmonary edema by a calcium channel blocker. ( Bärtsch, P; Maggiorini, M; Noti, C; Oelz, O; Ritter, M; Vock, P; Waber, U, 1992) |
| "Primary pulmonary hypertension is a progressive, fatal disease of unknown cause." | 2.67 | The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. ( Kaufmann, E; Levy, PS; Rich, S, 1992) |
| "The advantages of long-term administration of vasodilators in the treatment of chronic cor pulmonale were investigated after informed consent in 60 patients with obstructive respiratory insufficiency (56 men, 4 women, mean age 63." | 2.66 | One-year clinical study on nifedipine in the treatment of pulmonary hypertension in chronic obstructive lung disease. ( Arnaud, A; Philip-Joet, F; Saadjian, A; Surpas, P; Vestri, R, 1988) |
| "This long-term controlled study was undertaken to assess the haemodynamic effects of chronic administration of Nifedipine (N)." | 2.66 | Long-term treatment of chronic obstructive lung disease by Nifedipine: an 18-month haemodynamic study. ( Arnaud, AG; Philip-Joet, FF; Saadjian, AY; Vestri, R, 1988) |
| "Foridon is not indicated for the treatment of renal hypertension." | 2.66 | [Use of foridon in the treatment of arterial hypertension and hypertension of the lesser circulation]. ( Demidiuk, VT; Mikunis, RI; Monastyrskiĭ, IuI; Pshelutskiĭ, FF; Serkova, VK, 1988) |
| "Pretreatment with nifedipine significantly attenuated the hypoxia-induced increase in mean pulmonary artery pressure by 53% and of the mean pulmonary vascular resistance index by 50%." | 2.66 | Nifedipine attenuates acute hypoxic pulmonary vasoconstriction in patients with chronic obstructive pulmonary disease. ( Burghuber, OC, 1987) |
| "Primary pulmonary hypertension is a rare disease with a median survival of only 2." | 2.39 | [Therapy of primary pulmonary arterial hypertension: current status]. ( Solèr, M, 1994) |
| "Excessive pulmonary vascular remodeling is mediated by increased proliferation of pulmonary arterial smooth muscle cells (PASMC) due to PASMC dedifferentiation from a contractile or quiescent phenotype to a proliferative or synthetic phenotype." | 1.42 | Upregulated expression of STIM2, TRPC6, and Orai2 contributes to the transition of pulmonary arterial smooth muscle cells from a contractile to proliferative phenotype. ( Fernandez, RA; Gu, Y; Makino, A; Mehta, D; Smith, KA; Song, S; Tang, H; Tauseef, M; Wan, J; Yuan, JX, 2015) |
| "Oral nifedipine or placebo was administered to alternating patients." | 1.38 | Nifedipine for the treatment of high altitude pulmonary edema. ( Basnet, S; Deshwal, R; Iqbal, M, 2012) |
| "Myocyte apoptosis and muscle atrophy were significantly decreased with irbesartan compared with untreated CHF rats." | 1.31 | Beneficial effects on skeletal muscle of the angiotensin II type 1 receptor blocker irbesartan in experimental heart failure. ( Angelini, A; Battista Ambrosio, G; Dalla Libera, L; Ravara, B; Rossini, K; Sandri, M; Thiene, G; Vescovo, G, 2001) |
| "Pretreatment with indomethacin, isoproterenol, or nifedipine significantly reduced post-air-embolism lung water content to 85." | 1.30 | Pharmacologic modulation of pulmonary vascular permeability during air embolism. ( Huang, KL; Lin, YC, 1997) |
| " In these nonresponders, nine serious adverse events were observed with CCB (38%)." | 1.30 | Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. ( Fartoukh, M; Herve, P; Humbert, M; Jagot, JL; Parent, F; Simonneau, G; Sitbon, O; Taravella, O, 1998) |
| "Primary pulmonary hypertension is a rare, incurable, and progressive disease." | 1.29 | Primary pulmonary hypertension in pregnancy: a case report. ( Asseryanis, E; Egarter, C; Kiss, H; Kneussl, M; Putz, D, 1995) |
| "Nifedipine was administered in 20 mg doses hourly during right cardiac catheterization and was repeated after 1 hour until a decrease in systemic pressure occurred." | 1.29 | [Effect of large doses of nifedipine on pulmonary hypertension in patients with recurrent pulmonary thromboembolism]. ( Fijałkowska, A; Filipecki, S; Hajduk, B; Pałasiewicz, G; Polowiec, Z; Radomyski, A; Tomkowski, W, 1994) |
| "Nifedipine (10 mg/kg) was administered intraperitoneally every day." | 1.29 | The effect of nifedipine on monocrotaline-induced pulmonary hypertension in rats. ( Harada, Y; Inoue, M; Mori, C; Tanaka, O; Watanabe, K, 1993) |
| "The nifedipine effect was age related." | 1.28 | Long-term hemodynamic effects of nifedipine on congenital heart disease with Eisenmenger's mechanism in children. ( Schlemmer, M; Wimmer, M, 1992) |
| "Nifedipine was discontinued after 8 months due to lack of improvement in the patient's state." | 1.28 | [Treatment of primary pulmonary hypertension with high doses of nifedipine controlled by Doppler echocardiography]. ( Filipecki, S; Pasierski, T; Radomyski, A; Tomkowski, W; Torbicki, A, 1991) |
| " Under this aspect we examined 44 patients by right heart catheterisation at rest and at exercise before and after sublingual application of a single dose of 20 mg nifedipine (Corinfar) as well as under continuous dosage of 30-60 mg daily." | 1.28 | The influence of nifedipine (Corinfar) on pulmonary hypertension in chronic obstructive lung disease. ( Evers, H; Harzbecker, K; Orschekowski, H; Schauer, J; Schilling, W; Steiniger, L; Winkler, J, 1990) |
| "Pulmonary hypertension was produced by continuous intravenous administration of U46619 to halothane-anesthetized sheep." | 1.28 | Hemodynamic effects of diltiazem during vasoconstrictor pulmonary hypertension in sheep. ( Finn, JC; Pearl, RG, 1990) |
| "Nifedipine was found to be the most effective." | 1.28 | [A case of primary pulmonary hypertension with high venous thromboxane B2 concentration]. ( Abe, S; Kawakami, Y; Kishi, F; Miyamoto, K; Nagata, H; Nakano, T; Suzuki, A; Takahashi, S; Takai, S, 1990) |
| "Primary pulmonary hypertension is an uncommon but serious disease that often results in debilitating symptoms and early death." | 1.28 | [Evaluation of the effects of vasodilator therapy in primary pulmonary hypertension. Experience in 7 cases]. ( Aimè, E; Angoli, L; Arbustini, E; Bargiggia, G; Campana, C; Gavazzi, A; Graziano, G; Lanzarini, L; Montemartini, C; Mussini, A, 1990) |
| " During 12 weeks of prednisone treatment in a dosage of 40 mg daily, her condition markedly deteriorated clinically and hemodynamically as manifested by pulmonary artery pressure (PAP), pulmonary vascular resistance (PVR), cardiac output (CO), mixed venous O2 saturation, and systemic vascular resistance (SVR)." | 1.28 | Nifedipine and prazosin in the management of pulmonary hypertension in CREST syndrome. ( Dresner-Feigin, R; Galun, E; Glikson, M; Pollack, A; Rubinow, A, 1990) |
| "Primary pulmonary hypertension is a disease of unknown etiology." | 1.28 | [Nifedipine in primary pulmonary hypertension while waiting for heart-lung transplantation]. ( Petersen, TI; Svanegård, J; Thayssen, P, 1989) |
| "Nifedipine was then administered sublingually in a dose of 1 mg/kg and produced an immediate and dramatic improvement in the right radial artery pO2 that was sustained despite persistence of the right-to-left shunt." | 1.28 | [Efficacy of nifedipine on refractory hypoxemia associated with diaphragmatic hernia in the newborn infant. Apropos of a case]. ( Burguet, A; Destuynder, R; Fromentin, C; Menget, A, 1989) |
| "Nifedipine is a potent slow channel calcium antagonist and systemic vasodilator recently reported to attenuate hypoxic pulmonary vasoconstriction in man." | 1.26 | Inhibition of hypoxic pulmonary vasoconstriction by nifedipine. ( Kennedy, T; Summer, W, 1982) |
| "Nifedipine is a calcium antagonistic drug which reduces elevated vascular resistances." | 1.26 | Hemodynamic effects of nifedipine in pulmonary hypertension. ( Camerini, F; Fioretti, P; Klugmann, S; Salvi, A, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 144 (54.34) | 18.7374 |
| 1990's | 79 (29.81) | 18.2507 |
| 2000's | 24 (9.06) | 29.6817 |
| 2010's | 17 (6.42) | 24.3611 |
| 2020's | 1 (0.38) | 2.80 |
| Authors | Studies |
|---|---|
| Luks, AM | 2 |
| Swenson, ER | 2 |
| Parise, I | 1 |
| Li, Y | 1 |
| Zhang, Y | 2 |
| Saigal, A | 1 |
| Ng, WK | 1 |
| Tan, RB | 1 |
| Chan, SY | 1 |
| Fernandez, RA | 1 |
| Wan, J | 2 |
| Song, S | 2 |
| Smith, KA | 2 |
| Gu, Y | 1 |
| Tauseef, M | 1 |
| Tang, H | 1 |
| Makino, A | 2 |
| Mehta, D | 1 |
| Yuan, JX | 3 |
| Wang, RX | 1 |
| He, RL | 1 |
| Jiao, HX | 1 |
| Dai, M | 1 |
| Mu, YP | 1 |
| Hu, Y | 1 |
| Wu, ZJ | 1 |
| Sham, JS | 1 |
| Lin, MJ | 1 |
| Fan, Z | 1 |
| Chen, Y | 1 |
| Liu, H | 1 |
| Yanamandra, U | 1 |
| Nair, V | 1 |
| Singh, S | 1 |
| Gupta, A | 1 |
| Mulajkar, D | 1 |
| Yanamandra, S | 1 |
| Norgais, K | 1 |
| Mukherjee, R | 1 |
| Singh, V | 1 |
| Bhattachar, SA | 1 |
| Patyal, S | 1 |
| Grewal, R | 1 |
| Chopra, B | 1 |
| Haworth, SG | 2 |
| Hislop, AA | 1 |
| Cui, B | 1 |
| Cheng, YS | 1 |
| Dai, DZ | 2 |
| Li, N | 1 |
| Zhang, TT | 1 |
| Dai, Y | 2 |
| Plumley, C | 1 |
| Gorman, EM | 1 |
| El-Gendy, N | 1 |
| Bybee, CR | 1 |
| Munson, EJ | 1 |
| Berkland, C | 1 |
| Rodat-Despoix, L | 1 |
| Aires, V | 1 |
| Ducret, T | 1 |
| Marthan, R | 1 |
| Savineau, JP | 1 |
| Rousseau, E | 1 |
| Guibert, C | 1 |
| Bozbaş, SS | 1 |
| Bozbaş, H | 1 |
| Atar, A | 1 |
| Ulubay, G | 1 |
| Oner Eyüboğlu, F | 1 |
| Yilmaz, R | 1 |
| Kayikçioğlu, M | 1 |
| Kültürsay, H | 1 |
| Yang, Y | 1 |
| Gao, M | 1 |
| Guo, Y | 1 |
| Qiao, J | 1 |
| Bailey, DM | 1 |
| Dehnert, C | 1 |
| Menold, E | 1 |
| Castell, C | 1 |
| Schendler, G | 1 |
| Faoro, V | 1 |
| Gutowski, M | 1 |
| Evans, KA | 1 |
| Taudorf, S | 1 |
| James, PE | 1 |
| McEneny, J | 1 |
| Young, IS | 1 |
| Mairbäurl, H | 1 |
| Bärtsch, P | 4 |
| Berger, MM | 1 |
| Mou, XB | 1 |
| Li, SZ | 1 |
| Gao, YQ | 1 |
| Liou, FY | 1 |
| Ye, GL | 1 |
| Tang, HY | 1 |
| Zhou, XB | 1 |
| Cheng, GL | 1 |
| Hall, SM | 1 |
| Davie, N | 1 |
| Klein, N | 1 |
| Deshwal, R | 1 |
| Iqbal, M | 1 |
| Basnet, S | 1 |
| S K S, S | 1 |
| P, H | 1 |
| Mathew, T | 1 |
| S, S | 1 |
| M, C | 1 |
| Forrest, AS | 1 |
| Joyce, TC | 1 |
| Huebner, ML | 1 |
| Ayon, RJ | 1 |
| Wiwchar, M | 1 |
| Joyce, J | 1 |
| Freitas, N | 1 |
| Davis, AJ | 1 |
| Ye, L | 1 |
| Duan, DD | 1 |
| Singer, CA | 1 |
| Valencik, ML | 1 |
| Greenwood, IA | 1 |
| Leblanc, N | 1 |
| Jones, BE | 1 |
| Stokes, S | 1 |
| McKenzie, S | 1 |
| Nilles, E | 1 |
| Stoddard, GJ | 1 |
| Yamamura, A | 1 |
| Yamamura, H | 1 |
| Guo, Q | 1 |
| Zimnicka, AM | 1 |
| Ko, EA | 1 |
| Pohl, NM | 1 |
| Zeifman, A | 1 |
| Nagaoka, T | 1 |
| Morio, Y | 1 |
| Casanova, N | 1 |
| Bauer, N | 1 |
| Gebb, S | 1 |
| McMurtry, I | 1 |
| Oka, M | 2 |
| Andreassen, AK | 1 |
| Geiran, O | 1 |
| Madsen, S | 1 |
| Hognestad, A | 1 |
| Simonsen, S | 1 |
| Kanazawa, H | 1 |
| Tateishi, Y | 1 |
| Yoshikawa, J | 1 |
| Oriowo, MA | 1 |
| Schlag, K | 1 |
| Opitz, C | 1 |
| Wensel, R | 1 |
| Felix, S | 1 |
| Ewert, R | 1 |
| Maggiorini, M | 3 |
| Yuan, SH | 1 |
| Guan, L | 1 |
| Ji, M | 1 |
| Rosati, E | 1 |
| Butera, G | 1 |
| Bossone, E | 4 |
| De Felice, C | 1 |
| Latini, G | 1 |
| Uner, A | 1 |
| Dogan, M | 1 |
| Demirtas, M | 1 |
| Açikgöz, M | 1 |
| Temel, H | 1 |
| Kaya, A | 1 |
| Caksen, H | 1 |
| Khan, SA | 1 |
| Gelb, BD | 1 |
| Nguyen, KH | 1 |
| Stone, KS | 1 |
| Scordo, KA | 1 |
| Krikler, DM | 1 |
| Rowland, E | 1 |
| Ellrodt, AG | 1 |
| Singh, BN | 1 |
| Rees, J | 1 |
| Wise, JR | 1 |
| Feret, J | 1 |
| Bruet, A | 1 |
| Simon, N | 1 |
| Duruy, D | 1 |
| Nouailhat, F | 1 |
| Havel, V | 1 |
| Král, B | 2 |
| Eliás, J | 1 |
| Hamet, A | 2 |
| Cernohorský, D | 2 |
| Rubin, LJ | 4 |
| Coma-Canella, I | 1 |
| Lopez-Sendon, J | 1 |
| Drummond, WH | 1 |
| Gaucher, LR | 1 |
| Payen, DM | 1 |
| Minsart, PJ | 1 |
| Peltier, PM | 1 |
| Ordronneau, JJ | 1 |
| Grolleau, JY | 1 |
| Lunde, P | 1 |
| Rasmussen, K | 1 |
| Fisher, J | 2 |
| Borer, JS | 2 |
| Moses, JW | 1 |
| Goldberg, HL | 1 |
| Niarchos, AP | 1 |
| Whitman, HH | 1 |
| Mermelstein, M | 1 |
| Packer, M | 2 |
| Medina, N | 1 |
| Yushak, M | 1 |
| van der Wall, EE | 1 |
| Tuinzing, DB | 1 |
| Hes, J | 1 |
| Dickstein, PJ | 1 |
| Trindade, O | 1 |
| Goldberg, RN | 1 |
| Bancalari, E | 1 |
| Young, TE | 1 |
| Lundquist, LJ | 1 |
| Chesler, E | 2 |
| Weir, EK | 3 |
| Nicod, P | 1 |
| Hillis, LD | 2 |
| Firth, BG | 1 |
| Rich, S | 11 |
| Ganz, R | 1 |
| Levy, PS | 4 |
| Gassner, A | 3 |
| Pichler, M | 1 |
| Fridrich, L | 3 |
| Sykora, J | 1 |
| Tizek, H | 1 |
| Lenz, K | 1 |
| Krol, RC | 1 |
| Evans, AT | 1 |
| Albright, DP | 1 |
| Reilly, JM | 1 |
| Brown, J | 1 |
| Roman, M | 1 |
| Vacek, JL | 1 |
| Kennedy, TP | 2 |
| Michael, JR | 2 |
| Huang, CK | 1 |
| Kallman, CH | 1 |
| Zahka, K | 1 |
| Schlott, W | 1 |
| Summer, W | 2 |
| Tobey, MA | 1 |
| Arnman, K | 1 |
| Rydén, L | 1 |
| Smedgård, P | 1 |
| Thorhallsson, E | 1 |
| Olivari, MT | 1 |
| Levine, TB | 1 |
| Cohn, JN | 1 |
| Stanbrook, HS | 1 |
| Morris, KG | 2 |
| McMurtry, IF | 2 |
| Pannarale, G | 1 |
| Gaspardone, A | 1 |
| Acconcia, MC | 1 |
| Valente, A | 1 |
| Mélot, C | 1 |
| Naeije, R | 1 |
| Mols, P | 1 |
| Vandenbossche, JL | 1 |
| Denolin, H | 1 |
| De Feyter, PJ | 1 |
| Kerkkamp, HJ | 1 |
| de Jong, JP | 1 |
| Farber, HW | 1 |
| Karlinsky, JB | 1 |
| Faling, LJ | 1 |
| Klugmann, S | 3 |
| Salvi, A | 3 |
| Camerini, F | 3 |
| Douglas, JS | 1 |
| Saito, D | 1 |
| Haraoka, S | 1 |
| Yoshida, H | 2 |
| Kusachi, S | 1 |
| Yasuhara, K | 1 |
| Nishihara, M | 1 |
| Fukuhara, J | 1 |
| Hagashima, H | 1 |
| Ocken, S | 1 |
| Reinitz, E | 1 |
| Strom, J | 1 |
| Berkenboom, G | 1 |
| Sobolski, J | 1 |
| Stoupel, E | 1 |
| Durandy, Y | 1 |
| Pansard, Y | 1 |
| Mankikian, B | 1 |
| Dequirot, A | 1 |
| Kennedy, T | 1 |
| Wood, BA | 1 |
| Tortoledo, F | 1 |
| Luck, JC | 1 |
| Fennell, WH | 2 |
| Jezek, V | 1 |
| Michaljanic, A | 1 |
| Fucík, J | 1 |
| Jezková, L | 1 |
| Krása, H | 1 |
| Gaul, G | 1 |
| Blazek, G | 1 |
| Deutsch, E | 1 |
| Heeger, H | 1 |
| Levigard, RM | 1 |
| Assad, JE | 1 |
| Fioretti, P | 1 |
| Dalal, JJ | 1 |
| Griffiths, BE | 1 |
| Henderson, AH | 1 |
| Alberti, E | 1 |
| Thomas, D | 1 |
| Drobinski, G | 1 |
| Komajda, M | 1 |
| Grosgogeat, Y | 1 |
| Crowley, MR | 1 |
| Fineman, JR | 1 |
| Soifer, SJ | 1 |
| Prasad, N | 1 |
| Lang, CC | 1 |
| McAlpine, HM | 1 |
| Choy, AM | 1 |
| MacDonald, TM | 1 |
| Struthers, AD | 1 |
| Saadjian, A | 8 |
| Philip-Joët, F | 6 |
| Barret, A | 1 |
| Levy, S | 1 |
| Arnaud, A | 8 |
| Li, MR | 1 |
| Chen, SC | 1 |
| Ma, G | 1 |
| Ghali, JK | 1 |
| Goerre, S | 1 |
| Wenk, M | 1 |
| Lüscher, TF | 1 |
| Niroomand, F | 1 |
| Hohenhaus, E | 1 |
| Oelz, O | 3 |
| Reinhart, WH | 1 |
| Jolliet, P | 2 |
| Thorens, JB | 2 |
| Chevrolet, JC | 2 |
| Kiss, H | 1 |
| Egarter, C | 1 |
| Asseryanis, E | 1 |
| Putz, D | 1 |
| Kneussl, M | 1 |
| Volkova, LI | 2 |
| Shteĭngart, IuN | 1 |
| Weiser, MC | 1 |
| Majack, RA | 1 |
| Tucker, A | 1 |
| Orton, EC | 1 |
| Solèr, M | 1 |
| Husebye, ES | 1 |
| Wibell, L | 1 |
| Pałasiewicz, G | 1 |
| Tomkowski, W | 2 |
| Hajduk, B | 1 |
| Fijałkowska, A | 1 |
| Radomyski, A | 2 |
| Filipecki, S | 2 |
| Polowiec, Z | 1 |
| Machet, L | 1 |
| Callens, A | 1 |
| Machet, MC | 1 |
| Desveaux, B | 1 |
| Vaillant, L | 1 |
| Ben Jrad, I | 1 |
| Slimane, ML | 1 |
| Boujnah, MR | 1 |
| Ben Hamda, K | 1 |
| Ameur, Y | 1 |
| Partanen, J | 1 |
| Nieminen, MS | 1 |
| Luomanmäki, K | 1 |
| Bujak, K | 1 |
| Kozik, T | 1 |
| Inoue, M | 1 |
| Harada, Y | 1 |
| Watanabe, K | 1 |
| Mori, C | 1 |
| Tanaka, O | 1 |
| Inbar, S | 2 |
| Schrader, BJ | 3 |
| Kaufmann, E | 4 |
| Vestal, RE | 2 |
| Ogata, M | 1 |
| Ohe, M | 1 |
| Shirato, K | 1 |
| Takishima, T | 1 |
| Nootens, M | 2 |
| Kalra, L | 1 |
| Bone, MF | 1 |
| el Hawy, AM | 1 |
| Negm, IA | 1 |
| el-Rakaybe, A | 1 |
| Abdel-Maged, AI | 1 |
| Mansour, RE | 1 |
| Phillips, BG | 1 |
| Bauman, JL | 1 |
| Schoen, MD | 1 |
| Hoon, TJ | 1 |
| Chaouat, A | 1 |
| Kessler, R | 1 |
| Weitzenblum, E | 1 |
| Patole, SK | 1 |
| Finer, NN | 1 |
| Shimabukuro, M | 1 |
| Chibana, T | 1 |
| Nagamine, F | 1 |
| Takasu, N | 1 |
| Malik, AS | 1 |
| Warshafsky, S | 1 |
| Lehrman, S | 2 |
| Bulpa, P | 1 |
| Ritz, M | 1 |
| Huang, KL | 1 |
| Lin, YC | 1 |
| Bragulat, E | 1 |
| García, F | 1 |
| Fernández, F | 1 |
| Ballester, E | 1 |
| Villalta, J | 1 |
| Grau, JM | 1 |
| Gallagher, MM | 1 |
| Hart, CM | 1 |
| Vaughan, CJ | 1 |
| Sitbon, O | 1 |
| Humbert, M | 1 |
| Jagot, JL | 1 |
| Taravella, O | 1 |
| Fartoukh, M | 1 |
| Parent, F | 1 |
| Herve, P | 1 |
| Simonneau, G | 1 |
| Atz, AM | 1 |
| Wessel, DL | 1 |
| Ricciardi, MJ | 2 |
| Knight, BP | 1 |
| Martinez, FJ | 2 |
| Rubenfire, M | 4 |
| Antezana, AM | 1 |
| Antezana, G | 1 |
| Aparicio, O | 1 |
| Noriega, I | 1 |
| Velarde, FL | 1 |
| Richalet, JP | 1 |
| Easterling, TR | 1 |
| Ralph, DD | 1 |
| Schmucker, BC | 1 |
| Bîrsan, T | 1 |
| Kranz, A | 1 |
| Mares, P | 1 |
| Artemiou, O | 1 |
| Taghavi, S | 1 |
| Zuckermann, A | 1 |
| Klepetko, W | 1 |
| Olschewski, H | 1 |
| Ghofrani, HA | 1 |
| Walmrath, D | 1 |
| Schermuly, R | 1 |
| Temmesfeld-Wollbruck, B | 1 |
| Grimminger, F | 1 |
| Seeger, W | 1 |
| Fike, CD | 1 |
| Kaplowitz, MR | 1 |
| Horstman, DJ | 1 |
| McCall, DA | 1 |
| Frank, DU | 1 |
| Rich, GF | 1 |
| Barst, RJ | 2 |
| Bach, DS | 1 |
| Armstrong, WF | 1 |
| Collados, MT | 1 |
| Sandoval, J | 1 |
| López, S | 1 |
| Massó, FA | 1 |
| Páez, A | 1 |
| Borbolla, JR | 1 |
| Montaño, LF | 1 |
| Paciocco, G | 2 |
| Erba, H | 1 |
| Cockrill, BA | 1 |
| Kacmarek, RM | 1 |
| Fifer, MA | 1 |
| Bigatello, LM | 1 |
| Ginns, LC | 1 |
| Zapol, WM | 1 |
| Semigran, MJ | 1 |
| Golovina, VA | 1 |
| Platoshyn, O | 1 |
| Bailey, CL | 1 |
| Wang, J | 1 |
| Limsuwan, A | 1 |
| Sweeney, M | 1 |
| Bayraktar, Y | 1 |
| Tanaci, N | 1 |
| Egesel, T | 1 |
| Gököz, A | 1 |
| Balkanci, F | 1 |
| Dalla Libera, L | 1 |
| Ravara, B | 1 |
| Angelini, A | 1 |
| Rossini, K | 1 |
| Sandri, M | 1 |
| Thiene, G | 1 |
| Battista Ambrosio, G | 1 |
| Vescovo, G | 1 |
| Tamura, M | 1 |
| Kurumatani, H | 1 |
| Matsushita, T | 1 |
| Pielsticker, E | 1 |
| Gillespie, B | 1 |
| McMahon, CJ | 1 |
| Kadkin, J | 1 |
| Nihill, MR | 1 |
| Xu, JY | 1 |
| Li, BX | 1 |
| Cheng, SY | 1 |
| Wimmer, M | 4 |
| Schlemmer, M | 4 |
| Cheng, X | 1 |
| Ritter, M | 2 |
| Noti, C | 2 |
| Waber, U | 2 |
| Vock, P | 2 |
| Domenighetti, GM | 1 |
| Saglini, VG | 1 |
| Kaufmann, L | 1 |
| Vorob'ev, LP | 3 |
| Maev, IV | 3 |
| Davis, DA | 1 |
| Russo, P | 1 |
| Alpert, MA | 2 |
| Pressly, TA | 2 |
| Mukerji, V | 2 |
| Lambert, CR | 1 |
| Mukerji, B | 1 |
| Panayiotou, H | 1 |
| Sharp, GC | 2 |
| Poloński, L | 2 |
| Polońska, A | 2 |
| Tendera, M | 2 |
| Wodniecki, J | 2 |
| Krzywiecki, A | 2 |
| Pasierski, T | 1 |
| Torbicki, A | 1 |
| Prigogine, T | 1 |
| Waterlot, Y | 1 |
| Gottignies, P | 1 |
| Verhoeven, A | 1 |
| Decroly, P | 1 |
| Kaziulin, AN | 1 |
| Andreev, NG | 1 |
| Yuan, H | 1 |
| Uren, NG | 1 |
| Oakley, CM | 2 |
| Johnson, CE | 1 |
| Beekman, RH | 2 |
| Kostyshak, DA | 1 |
| Nguyen, T | 1 |
| Oh, DM | 1 |
| Amidon, GL | 1 |
| Ribeiro, PA | 1 |
| Sivanandan, V | 1 |
| Shaikh, A | 1 |
| Chalak, W | 1 |
| Zaman, L | 1 |
| Duran, CM | 1 |
| Liu, Z | 1 |
| Yu, RJ | 1 |
| Dubiel, JP | 1 |
| Nikodemowicz, M | 1 |
| Zmudka, K | 1 |
| Mazurek, S | 1 |
| Królikowski, T | 1 |
| Prielipp, RC | 2 |
| McLean, R | 1 |
| Rosenthal, MH | 2 |
| Pearl, RG | 3 |
| Salzer, U | 1 |
| Marx, M | 1 |
| Proll, E | 1 |
| Schauer, J | 2 |
| Orschekowski, H | 2 |
| Steiniger, L | 1 |
| Winkler, J | 1 |
| Schilling, W | 1 |
| Harzbecker, K | 1 |
| Evers, H | 1 |
| Sommer, G | 2 |
| Magometschnigg, D | 2 |
| Priol, A | 1 |
| Finn, JC | 1 |
| Nakano, T | 1 |
| Takai, S | 1 |
| Suzuki, A | 1 |
| Miyamoto, K | 1 |
| Nagata, H | 1 |
| Kishi, F | 1 |
| Abe, S | 1 |
| Kawakami, Y | 1 |
| Takahashi, S | 1 |
| Lanzarini, L | 1 |
| Gavazzi, A | 1 |
| Mussini, A | 1 |
| Graziano, G | 1 |
| Campana, C | 1 |
| Bargiggia, G | 1 |
| Angoli, L | 1 |
| Aimè, E | 1 |
| Arbustini, E | 1 |
| Montemartini, C | 1 |
| Luther, R | 1 |
| Wichert, H | 1 |
| Köhler, E | 1 |
| Banditt, P | 1 |
| Walther, H | 1 |
| Glikson, M | 1 |
| Pollack, A | 1 |
| Dresner-Feigin, R | 1 |
| Galun, E | 1 |
| Rubinow, A | 1 |
| Zhou, X | 1 |
| Morrison, DA | 1 |
| Gay, RG | 1 |
| Feldshon, D | 1 |
| Sampliner, RE | 1 |
| Petersen, TI | 1 |
| Svanegård, J | 1 |
| Thayssen, P | 1 |
| Palombo, C | 1 |
| Mian, M | 1 |
| Bertelli, A | 1 |
| Mazza, F | 1 |
| Morra, AM | 1 |
| Morra, MG | 1 |
| Catalano, M | 1 |
| Contiello, V | 1 |
| Polcino, A | 1 |
| Oida, A | 1 |
| Ogawa, K | 1 |
| Nagao, I | 1 |
| Tsukada, K | 1 |
| Yoshimura, M | 1 |
| Sawada, M | 3 |
| Chen, H | 1 |
| Wang, SZ | 1 |
| Bai, YR | 1 |
| Himmel, W | 1 |
| Paleev, NR | 1 |
| Tsa'rkova, LN | 1 |
| Uribe-Echevarria, EE | 1 |
| Baklykova, SN | 1 |
| Novoderezhkina, LB | 1 |
| Turetta, F | 1 |
| De Stefani, R | 1 |
| Milanesi, A | 1 |
| Cannizzaro, A | 1 |
| Stievano, N | 1 |
| Bossi, A | 1 |
| Simone, M | 1 |
| Davidson, A | 1 |
| Bossuyt, A | 1 |
| Dab, I | 1 |
| Dantzker, DR | 3 |
| D'Alonzo, GE | 3 |
| Gianotti, L | 2 |
| Fuentes, F | 1 |
| Nickeson, D | 1 |
| Emerson, M | 1 |
| Meurice, JC | 1 |
| Boutaud, P | 1 |
| Herpin, D | 1 |
| Ingrand, P | 1 |
| Boita, F | 1 |
| Underner, M | 1 |
| Patte, F | 1 |
| Vestri, R | 5 |
| Pohar, B | 1 |
| Grad, A | 1 |
| Mozina, M | 1 |
| Rakovec, P | 1 |
| Horvat, M | 1 |
| Burguet, A | 1 |
| Menget, A | 1 |
| Fromentin, C | 1 |
| Destuynder, R | 1 |
| Agostoni, P | 2 |
| Doria, E | 2 |
| Galli, C | 2 |
| Tamborini, G | 2 |
| Guazzi, MD | 1 |
| Buescher, P | 1 |
| Farrukh, I | 1 |
| Lodato, R | 1 |
| Rock, PC | 1 |
| Gottlieb, J | 1 |
| Gurtner, G | 1 |
| de la Monte, SM | 1 |
| Hutchins, GM | 1 |
| Shao, MG | 1 |
| Cai, YN | 1 |
| Deng, XX | 1 |
| Philip-Joft, F | 1 |
| Lagier, F | 1 |
| Joet, FP | 1 |
| Miyamori, R | 1 |
| Marutani, K | 1 |
| Norisue, H | 1 |
| Fukui, T | 1 |
| Handa, S | 2 |
| Hosoda, Y | 1 |
| Schranz, D | 1 |
| Huth, RG | 1 |
| Stopfkuchen, H | 1 |
| Jüngst, BK | 1 |
| Surpas, P | 1 |
| Saadjian, AY | 1 |
| Philip-Joet, FF | 1 |
| Arnaud, AG | 1 |
| Mikunis, RI | 1 |
| Monastyrskiĭ, IuI | 1 |
| Pshelutskiĭ, FF | 1 |
| Serkova, VK | 1 |
| Demidiuk, VT | 1 |
| Tran N'guyen, A | 1 |
| Torresani, J | 2 |
| Klicpera, M | 1 |
| Ebner, F | 2 |
| Sil'vestrov, VP | 1 |
| Surovov, IuA | 1 |
| Semin, SN | 1 |
| Pakulin, IA | 1 |
| Larin, NV | 1 |
| Köhler, W | 1 |
| von Jan, V | 1 |
| Schmidt, H | 1 |
| Corriveau, ML | 1 |
| Rosen, BJ | 1 |
| Keller, CA | 1 |
| Chun, DS | 1 |
| Dolan, GF | 1 |
| Hussein, A | 1 |
| Koch, I | 1 |
| Schmidt-Redemann, B | 1 |
| Brownlee, JR | 1 |
| Rosenthal, A | 1 |
| Mohsenifar, Z | 1 |
| Jasper, AC | 2 |
| Koerner, SK | 2 |
| Araki, Y | 2 |
| Tanaka, N | 1 |
| Kudoh, S | 1 |
| Sakaguchi, K | 2 |
| Fujita, K | 1 |
| Fiorentini, C | 1 |
| Guazzi, M | 1 |
| Wilczek, K | 1 |
| Coli, A | 1 |
| Ammirati, A | 1 |
| Dina, MA | 1 |
| Khosseĭn, A | 2 |
| Mukharliamov, NM | 1 |
| Mareev, VIu | 2 |
| Lobova, NM | 2 |
| Ageev, FT | 2 |
| Rozkovec, A | 1 |
| Stradling, JR | 1 |
| Shepherd, G | 1 |
| MacDermot, J | 1 |
| Dollery, CT | 1 |
| Winkler, A | 1 |
| Jackson, RW | 1 |
| Benge, JM | 1 |
| Vereshchagina, GN | 1 |
| Vasilenko, GP | 1 |
| Kuleshova, TV | 1 |
| Kasian, GF | 1 |
| Ninan, A | 1 |
| Duncan, WJ | 1 |
| Bingham, WT | 1 |
| Mersal, A | 1 |
| Tyrrell, MJ | 1 |
| Sankaran, K | 1 |
| Sazonova, LN | 1 |
| Berisha, S | 1 |
| Goda, A | 1 |
| Kastrati, A | 1 |
| Frasheri, A | 1 |
| Popa, Y | 1 |
| Paczek, A | 1 |
| Rydlewska-Sadowska, W | 1 |
| Johnson, DC | 1 |
| Joshi, RC | 1 |
| Mehta, R | 1 |
| Cunnington, AR | 1 |
| Hart, K | 1 |
| Kieras, K | 1 |
| Brundage, BH | 2 |
| Barreto, SM | 1 |
| de Freitas, FM | 2 |
| Grisanti, M | 1 |
| Vicencio, M | 1 |
| Barreto, BM | 1 |
| Mangieri, E | 1 |
| Puddu, E | 1 |
| Martuscelli, E | 1 |
| Lanti, M | 1 |
| Danesi, A | 1 |
| Nigri, A | 1 |
| Reale, A | 1 |
| Marmor, AT | 1 |
| Michaeli, S | 1 |
| Plich, M | 1 |
| Frankel, A | 1 |
| Schneeweiss, A | 1 |
| Mack, RJ | 1 |
| Likier, HM | 1 |
| Schiff, AN | 1 |
| Halpern, SM | 1 |
| Shah, PK | 1 |
| Goldberg, HS | 1 |
| Obata, Y | 1 |
| Burghuber, OC | 1 |
| Yamaguchi, S | 1 |
| Tsuiki, K | 1 |
| Hayasaka, M | 1 |
| Oguma, M | 1 |
| Ohta, I | 1 |
| Kaminishi, T | 1 |
| Sukekawa, H | 1 |
| Kanaya, T | 1 |
| Yasui, S | 1 |
| Bratel, T | 2 |
| Hedenstierna, G | 2 |
| Nyquist, O | 2 |
| Ripe, E | 2 |
| Fujii, I | 1 |
| Ohonishi, S | 1 |
| Yamazaki, H | 1 |
| Nakamura, Y | 1 |
| Sturani, C | 1 |
| Papiris, S | 1 |
| Galavotti, V | 1 |
| Gunella, G | 1 |
| Kochanek, PM | 1 |
| Zaritsky, A | 1 |
| Lehrman, SG | 1 |
| Hollander, RC | 1 |
| Hecht, SR | 1 |
| Berger, M | 1 |
| Berdoff, RL | 1 |
| Van Tosh, A | 1 |
| Stimola, JM | 1 |
| Woroszylska, M | 1 |
| Piotrowska, J | 1 |
| Ruzyłło, W | 1 |
| Lubiszewska, B | 1 |
| Freggiaro, V | 1 |
| Davi, R | 1 |
| Morelloni, S | 1 |
| Pareti, G | 1 |
| Allegri, M | 1 |
| Okada, O | 1 |
| Naito, T | 1 |
| Kohchi, F | 1 |
| Yamagishi, F | 1 |
| Kuriyama, T | 1 |
| Sugita, T | 1 |
| Watanabe, S | 1 |
| Hasebe, N | 1 |
| Onodera, S | 1 |
| Ohmiya, H | 1 |
| Tanaka, M | 1 |
| Sakamoto, K | 1 |
| Honda, Y | 1 |
| Ikeda, Y | 1 |
| Sakai, E | 1 |
| Kuwajima, T | 1 |
| Musante, R | 1 |
| Di Donato, M | 1 |
| Archer, SL | 1 |
| Yankovich, RD | 1 |
| Garzaniti, N | 1 |
| el Allaf, D | 1 |
| D'Orio, V | 1 |
| Cremers, S | 1 |
| Marcelle, R | 1 |
| Carlier, J | 1 |
| Winniford, MD | 1 |
| Aromatorio, GJ | 1 |
| Uretsky, BF | 1 |
| Reddy, PS | 1 |
| Santos Bouza, AA | 1 |
| López Pérez, JM | 1 |
| Philips, JB | 1 |
| Lyrene, RK | 1 |
| Leslie, GI | 1 |
| McDevitt, M | 1 |
| Cassady, G | 1 |
| Batra, AK | 1 |
| Segall, PH | 1 |
| Ahmed, T | 1 |
| Gladman, DD | 1 |
| Sternberg, L | 1 |
| Ohar, J | 1 |
| Polatty, C | 1 |
| Robichaud, A | 1 |
| Fowler, A | 1 |
| Vetrovec, G | 1 |
| Glauser, F | 1 |
| Muramoto, A | 1 |
| Caldwell, J | 1 |
| Albert, RK | 1 |
| Lakshminarayan, S | 1 |
| Butler, J | 1 |
| Domenighetti, G | 1 |
| Guintoli, A | 1 |
| Galiè, N | 1 |
| Sanguinetti, M | 1 |
| Marrozzini, C | 1 |
| Magnani, B | 1 |
| Fudman, EJ | 1 |
| Kelling, DG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Calcium Channel Blockers in Nitric Oxide Non-responder Pulmonary Arterial Hypertension.[NCT01645826] | 0 participants (Actual) | Interventional | 2012-07-31 | Withdrawn (stopped due to no participants agreed to enroll since study start) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
24 reviews available for nifedipine and Hypertension, Pulmonary
| Article | Year |
|---|---|
COVID-19 Lung Injury and High-Altitude Pulmonary Edema. A False Equation with Dangerous Implications.
Topics: Acetazolamide; Altitude Sickness; Betacoronavirus; Carbonic Anhydrase Inhibitors; Coronavirus Infect | 2020 |
Travelling safely to places at high altitude - Understanding and preventing altitude illness.
Topics: Acclimatization; Acetazolamide; Altitude; Altitude Sickness; Anticonvulsants; Antiemetics; Calcium C | 2017 |
Research advances in pathogenesis and prophylactic measures of acute high altitude illness.
Topics: Acetazolamide; Acute Disease; Altitude Sickness; Calcium Channel Blockers; Carbonic Anhydrase Inhibi | 2018 |
Calcium channel blockers for pulmonary arterial hypertension.
Topics: Aged; Benzimidazoles; Benzoates; Calcium Channel Blockers; Humans; Hypertension, Pulmonary; Middle A | 2015 |
[Current approach to the treatment of pulmonary arterial hypertension and our experience in the Cardiology Department of Medicine Faculty of Ege University].
Topics: Antihypertensive Agents; Diltiazem; Disease Progression; Epoprostenol; Humans; Hypertension, Pulmona | 2009 |
High altitude-induced pulmonary oedema.
Topics: Acclimatization; Altitude Sickness; Disease Susceptibility; Humans; Hypertension, Pulmonary; Nifedip | 2006 |
Understanding the calcium channel blockers.
Topics: Action Potentials; Angina Pectoris; Animals; Arrhythmias, Cardiac; Arteriosclerosis; Calcium; Calciu | 1984 |
Clinical value of calcium antagonists in treatment of cardiovascular disorders.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina Pectoris, Variant; Arrhythmias, Cardiac; Calciu | 1983 |
Clinical applications of slow channel blocking compounds.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Blood Platelets; Blood Vessels; Calcium | 1983 |
Cardiovascular effects of vasodilator therapy for pulmonary arterial hypertension.
Topics: Cardiac Output; Echocardiography; Hemodynamics; Humans; Hydralazine; Hypertension, Pulmonary; Hypote | 1983 |
Persistent pulmonary hypertension of the neonate (persistent fetal circulation syndrome).
Topics: Acetylcholine; Calcium; Catecholamines; Epoprostenol; Homeostasis; Humans; Hypertension, Pulmonary; | 1983 |
[Early pulmonary hypertension: current therapeutic prospectives].
Topics: Calcium Channel Blockers; Captopril; Diazoxide; Diltiazem; Humans; Hydralazine; Hypertension, Pulmon | 1982 |
[Therapy of primary pulmonary arterial hypertension: current status].
Topics: Humans; Hypertension, Pulmonary; Lung Transplantation; Nifedipine; Prognosis; Pulmonary Artery; Pulm | 1994 |
Experimental and clinical effects of magnesium infusion in the treatment of neonatal pulmonary hypertension.
Topics: Animals; Blood Coagulation; Calcium Channel Blockers; Cyclic AMP; Cyclic GMP; Disease Models, Animal | 1995 |
Sustained improvement of pulmonary haemodynamics with low-dose of nifedipine in primary pulmonary hypertension.
Topics: Adult; Calcium Channel Blockers; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electr | 1996 |
Meta-analysis of the long-term effect of nifedipine for pulmonary hypertension.
Topics: Antihypertensive Agents; Clinical Trials as Topic; Humans; Hypertension, Pulmonary; Nifedipine; Time | 1997 |
Do no harm.
Topics: Calcium Channel Blockers; Contraindications; Echocardiography; Heart Septum; Heart Ventricles; Human | 1999 |
Reversible pulmonary hypertension in POEMS syndrome--another etiology of triggered pulmonary vasculopathy?
Topics: Adrenal Cortex Hormones; Diuretics; Drug Therapy, Combination; Female; Humans; Hypertension, Pulmona | 2000 |
[Pathophysiology, prevention and therapy of altitude pulmonary edema].
Topics: Aldosterone; Altitude Sickness; Cell Membrane Permeability; Epinephrine; Humans; Hypertension, Pulmo | 1992 |
[Calcium antagonists: accounts on new perspectives of their use and an update on side effects].
Topics: Adult; Animals; Asthma; Calcium Channel Blockers; Cardiovascular Diseases; Diltiazem; Esophageal Ach | 1989 |
[Effects of nifedipine in patients with chronic obstructive bronchitis and pulmonary hypertension undergoing artificial respiration].
Topics: Hemodynamics; Humans; Hypertension, Pulmonary; Lung Diseases, Obstructive; Nifedipine; Oxygen; Respi | 1989 |
[Nifedipine in the treatment of pulmonary hypertension. I--Primary pulmonary hypertension].
Topics: Adult; Blood Pressure; Female; Humans; Hypertension, Pulmonary; Male; Nifedipine; Vascular Resistanc | 1986 |
Calcium antagonists in patients with cardiovascular disease. Current perspectives.
Topics: Angina Pectoris; Angina Pectoris, Variant; Atrial Fibrillation; Atrial Flutter; Benzazepines; Cardio | 1985 |
Therapeutic application of calcium-channel antagonists for pulmonary hypertension.
Topics: Animals; Calcium Channel Blockers; Cattle; Diltiazem; Hemodynamics; Humans; Hypertension, Pulmonary; | 1985 |
26 trials available for nifedipine and Hypertension, Pulmonary
| Article | Year |
|---|---|
Managing High-Altitude Pulmonary Edema with Oxygen Alone: Results of a Randomized Controlled Trial.
Topics: Adult; Altitude; Altitude Sickness; Anti-Inflammatory Agents; Combined Modality Therapy; Dexamethaso | 2016 |
Comparative effects of losartan and nifedipine therapy on exercise capacity, Doppler echocardiographic parameters and endothelin levels in patients with secondary pulmonary hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Diastol | 2010 |
Calcium antagonists, diltiazem and nifedipine, protect broilers against low temperature-induced pulmonary hypertension and pulmonary vascular remodeling.
Topics: Animals; Calcium Channel Blockers; Chickens; Cold Temperature; Diltiazem; Hypertension, Pulmonary; M | 2010 |
Acute effects of nifedipine administration in pulmonary haemodynamics and oxygen delivery during exercise in patients with chronic obstructive pulmonary disease: implication of the angiotensin-converting enzyme gene polymorphisms.
Topics: Aged; Biological Transport; Calcium Channel Blockers; Cross-Over Studies; Double-Blind Method; Exerc | 2004 |
Nifedipine inhibits the effects of almitrine in patients suffering from pulmonary artery hypertension secondary to chronic obstructive pulmonary disease.
Topics: Almitrine; Blood Gas Analysis; Cardiac Catheterization; Double-Blind Method; Female; Hemodynamics; H | 1993 |
Endothelin-1 in pulmonary hypertension associated with high-altitude exposure.
Topics: Adult; Altitude; Altitude Sickness; Arteries; Blood Gas Analysis; Double-Blind Method; Endothelins; | 1995 |
Effect of nifedipine on physiologic shunting and oxygenation in chronic obstructive pulmonary disease.
Topics: Administration, Sublingual; Blood Gas Analysis; Blood Pressure; Catheterization, Swan-Ganz; Female; | 1993 |
Short-term effectiveness of nifedipine in secondary pulmonary hypertension.
Topics: Adult; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Nifedipine; Treatment Outcome | 1993 |
Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis.
Topics: Administration, Inhalation; Adult; Aged; Atrial Function, Right; Calcium Channel Blockers; Drug Ther | 1999 |
Echocardiographic predictors of an adverse response to a nifedipine trial in primary pulmonary hypertension: diminished left ventricular size and leftward ventricular septal bowing.
Topics: Administration, Oral; Adult; Blood Pressure; Calcium Channel Blockers; Echocardiography; Female; Hea | 1999 |
Characterization of von Willebrand factor in primary pulmonary hypertension.
Topics: Adrenergic beta-Agonists; Adult; Antigens; Biomarkers; Blotting, Western; Calcium Channel Blockers; | 1999 |
Prevention and treatment of high altitude pulmonary edema by a calcium channel blocker.
Topics: Acute Disease; Administration, Sublingual; Adult; Altitude Sickness; Double-Blind Method; Humans; Hy | 1992 |
The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.
Topics: Adult; Blood Pressure; Calcium Channel Blockers; Diltiazem; Humans; Hypertension, Pulmonary; Nifedip | 1992 |
[Effects of corinfar, nitrosorbide and apressin on external respiration and blood flow in chronic obstructive bronchitis].
Topics: Blood Circulation; Bronchitis; Humans; Hydralazine; Hypertension, Pulmonary; Isosorbide Dinitrate; N | 1992 |
[Drug therapy of pulmonary and portal hypertension in liver cirrhosis].
Topics: Adult; Aged; Antihypertensive Agents; Humans; Hypertension, Portal; Hypertension, Pulmonary; Isosorb | 1991 |
[Modification of pulmonary hypertension in patients with chronic obstructive lung diseases using calcium antagonists in an acute trial].
Topics: Administration, Sublingual; Adult; Aged; Clinical Trials as Topic; Humans; Hypertension, Pulmonary; | 1989 |
[Nifedipine treatment of pulmonary hypertension as a complication of chronic obstructive diseases of the lungs].
Topics: Adult; Anti-Arrhythmia Agents; Clinical Trials as Topic; Female; Hemodynamics; Humans; Hypertension, | 1989 |
[Long-term treatment of pulmonary hypertension in chronic obstructive bronchopneumopathies with nifedipine. Hemodynamic study over 18 months].
Topics: Female; Follow-Up Studies; Hemodynamics; Humans; Hypertension, Pulmonary; Lung Diseases, Obstructive | 1989 |
[Long-term clinical study of nifedipine in the treatment of pulmonary arterial hypertension in chronic obstructive bronchopneumopathies].
Topics: Clinical Trials as Topic; Female; Humans; Hypertension, Pulmonary; Lung Diseases, Obstructive; Male; | 1987 |
[Hemodynamic effects of the administration of nifedipine over an 18-month period in pulmonary arterial hypertension in chronic obstructive bronchopneumopathies].
Topics: Hemodynamics; Humans; Hypertension, Pulmonary; Lung Diseases, Obstructive; Nifedipine | 1988 |
One-year clinical study on nifedipine in the treatment of pulmonary hypertension in chronic obstructive lung disease.
Topics: Aged; Clinical Trials as Topic; Dyspnea; Female; Humans; Hypertension, Pulmonary; Lung Diseases, Obs | 1988 |
Long-term treatment of chronic obstructive lung disease by Nifedipine: an 18-month haemodynamic study.
Topics: Clinical Trials as Topic; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Lung Diseases, Obst | 1988 |
[Use of foridon in the treatment of arterial hypertension and hypertension of the lesser circulation].
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Clonidine; Drug Syne | 1988 |
[Long-term use of the calcium antagonist nifedipine (corinfar) in the treatment of patients with primary pulmonary hypertension].
Topics: Adolescent; Adult; Antihypertensive Agents; Clinical Trials as Topic; Dose-Response Relationship, Dr | 1988 |
Treatment of pulmonary hypertension with diltiazem in a child with bronchopulmonary dysplasia.
Topics: Albuterol; Bronchopulmonary Dysplasia; Child, Preschool; Diltiazem; Humans; Hydralazine; Hypertensio | 1988 |
Nifedipine attenuates acute hypoxic pulmonary vasoconstriction in patients with chronic obstructive pulmonary disease.
Topics: Aged; Cardiac Output; Female; Humans; Hypertension, Pulmonary; Lung Diseases, Obstructive; Male; Mid | 1987 |
215 other studies available for nifedipine and Hypertension, Pulmonary
| Article | Year |
|---|---|
Development of controlled release inhalable polymeric microspheres for treatment of pulmonary hypertension.
Topics: Administration, Inhalation; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Humans; Hy | 2013 |
Upregulated expression of STIM2, TRPC6, and Orai2 contributes to the transition of pulmonary arterial smooth muscle cells from a contractile to proliferative phenotype.
Topics: Animals; Calcium; Calcium Channel Blockers; Calcium Channels; Calcium Channels, L-Type; Calcium Sign | 2015 |
Ginsenoside Rb1 attenuates agonist-induced contractile response via inhibition of store-operated calcium entry in pulmonary arteries of normal and pulmonary hypertensive rats.
Topics: Animals; Calcium; Calcium Channels; Cell Hypoxia; Cells, Cultured; Disease Models, Animal; Endotheli | 2015 |
Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006.
Topics: Adolescent; Bosentan; Case-Control Studies; Child; Child, Preschool; Epoprostenol; Female; Heart Def | 2009 |
CPU0213, a non-selective ETA/ETB receptor antagonist, improves pulmonary arteriolar remodeling of monocrotaline-induced pulmonary hypertension in rats.
Topics: Animals; Arterioles; Calcium Channel Blockers; Disease Models, Animal; Endothelin A Receptor Antagon | 2009 |
Nifedipine nanoparticle agglomeration as a dry powder aerosol formulation strategy.
Topics: Aerosols; Calcium Channel Blockers; Colloids; Drug Delivery Systems; Drug Stability; Hypertension, P | 2009 |
Signalling pathways involved in the contractile response to 5-HT in the human pulmonary artery.
Topics: Aged; Calcium; Escin; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Muscle Contraction | 2009 |
Losartan and nifedipine therapy in patients with secondary pulmonary hypertension.
Topics: Anti-Arrhythmia Agents; Blood Pressure; Endothelium, Vascular; Humans; Hypertension, Pulmonary; Losa | 2010 |
High-altitude pulmonary hypertension is associated with a free radical-mediated reduction in pulmonary nitric oxide bioavailability.
Topics: Adult; Altitude Sickness; Antihypertensive Agents; Female; Free Radicals; Hemodynamics; Humans; Hype | 2010 |
[Hemodynamic effects of aminophylline and nifedipine in patients with high altitude pulmonary edema].
Topics: Adult; Altitude; Altitude Sickness; Aminophylline; Humans; Hypertension, Pulmonary; Male; Nifedipine | 2004 |
Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment.
Topics: Adolescent; Antihypertensive Agents; Bosentan; Child; Child, Preschool; Drug Therapy, Combination; E | 2011 |
Nifedipine for the treatment of high altitude pulmonary edema.
Topics: Adaptation, Physiological; Adult; Altitude Sickness; Bed Rest; Calcium Channel Blockers; Cross-Secti | 2012 |
Nifedipine inhibits hypoxia induced transvascular leakage through down regulation of NFkB.
Topics: Altitude Sickness; Animals; Calcium Channel Blockers; Capillary Permeability; Disease Models, Animal | 2012 |
Increased TMEM16A-encoded calcium-activated chloride channel activity is associated with pulmonary hypertension.
Topics: Animals; Anoctamin-1; Calcium Channel Blockers; Chloride Channel Agonists; Chloride Channels; Cycloo | 2012 |
Management of high altitude pulmonary edema in the Himalaya: a review of 56 cases presenting at Pheriche medical aid post (4240 m).
Topics: Acetazolamide; Altitude Sickness; Dexamethasone; Emergency Treatment; Female; Humans; Hypertension, | 2013 |
Dihydropyridine Ca(2+) channel blockers increase cytosolic [Ca(2+)] by activating Ca(2+)-sensing receptors in pulmonary arterial smooth muscle cells.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Signaling; Cells, Cultured; Cyt | 2013 |
Rho/Rho kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats.
Topics: Amides; Animals; Blood Pressure; Chromones; Enzyme Inhibitors; Hypertension, Pulmonary; Hypoxia; Ind | 2004 |
[Pulmonary arterial hypertension treated with prostacyclin or calcium blockers].
Topics: Administration, Oral; Adult; Antihypertensive Agents; Calcium Channel Blockers; Epoprostenol; Female | 2003 |
Chloride channels and alpha1-adrenoceptor-mediated pulmonary artery smooth muscle contraction: effect of pulmonary hypertension.
Topics: Animals; Bumetanide; Calcium Channel Blockers; Chloride Channels; Chloride-Bicarbonate Antiporters; | 2004 |
[Pulmonary hypertension in hereditary haemorrhagic teleangiectasia (Rendu-Osler-Weber disease). Progression over 10 years].
Topics: Anticoagulants; Antihypertensive Agents; Bosentan; Calcium Channel Blockers; Diuretics; Endothelin R | 2005 |
CPU0507, an endothelin receptor antagonist, improves rat hypoxic pulmonary artery hypertension and constriction in vivo and in vitro.
Topics: Animals; Antihypertensive Agents; Endothelin Receptor Antagonists; Heart; Hypertension, Pulmonary; H | 2006 |
Inhaled nitric oxide and oral nifedipine in a preterm infant with bronchopulmonary dysplasia and pulmonary hypertension.
Topics: Administration, Inhalation; Administration, Oral; Bronchodilator Agents; Bronchopulmonary Dysplasia; | 2007 |
Comparison of nifedipine and captopril in children with pulmonary hypertension due to bronchopneumonia.
Topics: Antihypertensive Agents; Blood Gas Analysis; Bronchopneumonia; Captopril; Child, Preschool; Drug The | 2008 |
Evaluation of pulmonary artery banding in the setting of ventricular septal defects and severely elevated pulmonary vascular resistance.
Topics: Adolescent; Cardiac Catheterization; Child; Comorbidity; Constriction; Coronary Circulation; Fatal O | 2006 |
Treatment of pulmonary hypertension in chronic bronchitis and emphysema.
Topics: Adrenergic beta-Agonists; Almitrine; Bronchitis; Humans; Hypertension, Pulmonary; Nifedipine; Pipera | 1984 |
Nifedipine in the treatment of primary pulmonary hypertension.
Topics: Adult; Cardiomegaly; Electrocardiography; Female; Humans; Hypertension, Pulmonary; Nifedipine; Physi | 1983 |
[Chronic obstructive bronchopneumopathies. Effect of nifedipine during the exercise test].
Topics: Adult; Aged; Exercise Test; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Lung Diseases, Ob | 1983 |
[Spiroergometry in patients with hypoxic pulmonary hypertension treated with Corinfar].
Topics: Adult; Humans; Hypertension, Pulmonary; Lung Diseases, Obstructive; Male; Middle Aged; Nifedipine; O | 1984 |
Haemodynamic effects of nifedipine, nitroglycerine and prazosin in pulmonary hypertension following ingestion of toxic oil.
Topics: Adolescent; Adult; Child; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; | 1983 |
Effects of nifedipine on pulmonary arterial hypertension in patients with respiratory insufficiency without acute failure.
Topics: Aged; Blood Pressure; Carbon Dioxide; Chronic Disease; Forced Expiratory Flow Rates; Heart Rate; Hum | 1984 |
Long-term beneficial effect of nifedipine in primary pulmonary hypertension.
Topics: Adult; Blood Pressure; Cardiac Output; Electrocardiography; Humans; Hypertension, Pulmonary; Male; N | 1984 |
Hemodynamic effects of nifedipine versus hydralazine in primary pulmonary hypertension.
Topics: Blood Pressure; Cardiac Output; Heart Rate; Hemodynamics; Humans; Hydralazine; Hypertension, Pulmona | 1984 |
Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease.
Topics: Adult; Calcium Channel Blockers; Cardiac Output; Exercise Test; Female; Hemodynamics; Humans; Hydral | 1984 |
[Gingival hyperplasia: a possible side effect of nifedipine].
Topics: Adult; Female; Gingival Hyperplasia; Humans; Hypertension, Pulmonary; Nifedipine | 1984 |
The effect of calcium antagonists on hypoxic pulmonary hypertension in the piglet.
Topics: Animals; Animals, Newborn; Cardiac Output; Hypertension, Pulmonary; Hypoxia; Nifedipine; Pulmonary W | 1984 |
Comparative effects of nifedipine, verapamil, and diltiazem on experimental pulmonary hypertension.
Topics: Animals; Benzazepines; Blood Pressure; Cardiac Output; Diltiazem; Dinoprost; Dogs; Dose-Response Rel | 1983 |
Treatment of primary pulmonary hypertension with nifedipine. A hemodynamic and scintigraphic evaluation.
Topics: Adolescent; Adult; Aorta; Blood Pressure; Cardiac Output; Female; Heart Rate; Humans; Hypertension, | 1983 |
Comparative actions of hydralazine, nifedipine and amrinone in primary pulmonary hypertension.
Topics: Adult; Aminopyridines; Amrinone; Cardiac Catheterization; Cardiac Output; Female; Humans; Hydralazin | 1983 |
[Effect of nifedipine on hemodynamics in precapillary pulmonary hypertension at rest and during exertion].
Topics: Adult; Blood Pressure; Female; Heart Rate; Hemodynamics; Humans; Hydrogen-Ion Concentration; Hyperte | 1983 |
Primary pulmonary hypertension, nifedipine, and hypoxemia.
Topics: Female; Humans; Hypertension, Pulmonary; Nifedipine; Oxygen | 1984 |
Nifedipine and pulmonary hypertension.
Topics: Humans; Hypertension, Pulmonary; Lung; Nifedipine; Vascular Resistance | 1984 |
Nifedipine and primary pulmonary hypertension.
Topics: Hemodynamics; Humans; Hypertension, Pulmonary; Nifedipine | 1984 |
Nifedipine inhibits hypoxic pulmonary vasoconstriction during rest and exercise in patients with chronic obstructive pulmonary disease. A controlled double-blind study.
Topics: Aged; Double-Blind Method; Hemodynamics; Humans; Hypertension, Pulmonary; Lung Diseases, Obstructive | 1984 |
Nifedipine in primary pulmonary hypertension.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Hypertension, Pulmonary; Nifedipine; Pulmon | 1984 |
Felodipine in primary pulmonary hypertension. Report of two cases.
Topics: Adult; Antihypertensive Agents; Felodipine; Female; Hemodynamics; Humans; Hypertension, Pulmonary; N | 1984 |
Hemodynamic effects of nifedipine at rest and during exercise in primary pulmonary hypertension.
Topics: Adolescent; Adult; Aged; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; N | 1984 |
Prevention and reversal of hypoxic pulmonary hypertension by calcium antagonists.
Topics: Animals; Dimethyl Sulfoxide; Hydralazine; Hypertension, Pulmonary; Hypoxia; Male; Nifedipine; Pulmon | 1984 |
Effects of nifedipine on ventilation/perfusion matching in primary pulmonary hypertension.
Topics: Female; Humans; Hypertension, Pulmonary; Middle Aged; Nifedipine; Pyridines; Ventilation-Perfusion R | 1983 |
Sustained beneficial effect of nifedipine in primary pulmonary hypertension.
Topics: Adult; Female; Humans; Hypertension, Pulmonary; Nifedipine; Pyridines | 1983 |
Fatal outcome following nifedipine for pulmonary hypertension.
Topics: Calcium Channel Blockers; Heart Arrest; Humans; Hypertension, Pulmonary; Male; Middle Aged; Nifedipi | 1983 |
Calcium antagonists in heart failure.
Topics: Aortic Valve Insufficiency; Calcium Channel Blockers; Coronary Disease; Diltiazem; Heart Failure; He | 1983 |
Hemodynamic effects of nifedipine in primary pulmonary hypertension.
Topics: Adult; Exercise Test; Female; Hemodynamics; Humans; Hydralazine; Hypertension, Pulmonary; Nifedipine | 1983 |
Primary pulmonary hypertension improved by long-term oral administration of nifedipine.
Topics: Administration, Oral; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Middle Aged; Nifedipine | 1983 |
Nifedipine treatment for pulmonary hypertension in a patient with systemic sclerosis.
Topics: Cardiac Catheterization; Humans; Hypertension, Pulmonary; Male; Middle Aged; Nifedipine; Pyridines; | 1983 |
Failure of nifedipine treatment in primary pulmonary hypertension.
Topics: Adult; Diazoxide; Female; Humans; Hypertension, Pulmonary; Nifedipine; Pyridines | 1982 |
[Comparative effects of tolazoline and nifedipine on hypoxic pulmonary arterial hypertension in the dog (author's transl)].
Topics: Animals; Dogs; Hypertension, Pulmonary; Hypoxia; Nifedipine; Pulmonary Circulation; Pyridines; Tolaz | 1982 |
Hydralazine in pulmonary hypertension.
Topics: Humans; Hydralazine; Hypertension, Pulmonary; Lung Diseases, Obstructive; Nifedipine | 1982 |
Inhibition of hypoxic pulmonary vasoconstriction by nifedipine.
Topics: Animals; Calcium Channel Blockers; Depression, Chemical; Dose-Response Relationship, Drug; Hypertens | 1982 |
Rapid attenuation of response to nifedipine in primary pulmonary hypertension.
Topics: Adult; Female; Humans; Hypertension, Pulmonary; Nifedipine; Pyridines; Vascular Resistance | 1982 |
[The effect of nifedipine on pulmonary hypertension].
Topics: Hemodynamics; Humans; Hypertension, Pulmonary; Nifedipine; Pyridines | 1982 |
[A case of chronic pulmonary hypertension after fenfluramine intake].
Topics: Chronic Disease; Female; Fenfluramine; Humans; Hypertension, Pulmonary; Middle Aged; Nifedipine; Obe | 1982 |
[Use of nifedipine in primary arterial pulmonary hypertension].
Topics: Female; Hemodynamics; Humans; Hypertension, Pulmonary; Middle Aged; Nifedipine; Pyridines | 1982 |
Hemodynamic effects of nifedipine in pulmonary hypertension.
Topics: Adult; Aged; Cardiac Output; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Age | 1982 |
Primary pulmonary hypertension: effects of nifedipine.
Topics: Adult; Female; Heart Failure; Humans; Hypertension, Pulmonary; Nifedipine; Pyridines | 1981 |
Primary pulmonary hypertension: effects of nifedipine.
Topics: Adult; Diazoxide; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Nifedipine; Pulmonary Arter | 1980 |
[Primary pulmonary arterial hypertension. Trial treatment with nifedipine, diazoxide and isoproterenol].
Topics: Diazoxide; Drug Therapy, Combination; Female; Humans; Hypertension, Pulmonary; Isoproterenol; Middle | 1980 |
HA1004, an intracellular calcium antagonist, selectively attenuates pulmonary hypertension in newborn lambs.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Animals, Newborn; Calci | 1994 |
Raised plasma concentrations of brain natriuretic peptide in pulmonary arterial hypertension.
Topics: Female; Humans; Hypertension, Pulmonary; Middle Aged; Natriuretic Peptide, Brain; Nerve Tissue Prote | 1995 |
[Comparative effects of calcium channel blockers and L-arginine on chronic intermittent hypoxic pulmonary hypertension in rats].
Topics: Animals; Arginine; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Hypoxia; Male; Nifedipin | 1994 |
Effect of nifedipine on pulmonary hemodynamics.
Topics: Blood Pressure; Hemodynamics; Humans; Hypertension, Pulmonary; Hypertrophy, Left Ventricular; Nifedi | 1995 |
Pulmonary vascular reactivity in severe pulmonary hypertension associated with mixed connective tissue disease.
Topics: Adult; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Mixed Connective Tissue Disease; Nifed | 1995 |
Primary pulmonary hypertension in pregnancy: a case report.
Topics: Adult; Female; Heparin, Low-Molecular-Weight; Humans; Hypertension, Pulmonary; Nifedipine; Pregnancy | 1995 |
[Individual approach to vasodilator treatment of pulmonary hypertension in chronic bronchitis].
Topics: Adult; Aminophylline; Bronchitis; Chronic Disease; Humans; Hydralazine; Hypertension, Pulmonary; Mid | 1994 |
Static tension is associated with increased smooth muscle cell DNA synthesis in rat pulmonary arteries.
Topics: Animals; Blood Pressure; Bromodeoxyuridine; Cell Division; DNA; Endothelium, Vascular; Hypertension, | 1995 |
[Survival--a question of active treatment. High-dose calcium blockers in pulmonary hypertension].
Topics: Adult; Calcium Channel Blockers; Diltiazem; Female; Humans; Hypertension, Pulmonary; Nifedipine; Pro | 1994 |
[Effect of large doses of nifedipine on pulmonary hypertension in patients with recurrent pulmonary thromboembolism].
Topics: Adult; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Nifedipine; Pulmonary Embol | 1994 |
NIP-121 is more effective than nifedipine in acutely reversing chronic pulmonary hypertension.
Topics: Altitude; Animals; Chronic Disease; Glyburide; Hemodynamics; Hypertension, Pulmonary; Hypoxia; Male; | 1993 |
Pulmonary hypertension in systemic lupus erythematosus--treatment with high dose nifedipine therapy?
Topics: Adult; Female; Humans; Hypertension, Pulmonary; Lupus Erythematosus, Systemic; Nifedipine | 1993 |
[Prognosis and treatment of chronic cor pulmonale].
Topics: Adult; Aged; Aged, 80 and over; Cardiomyopathy, Restrictive; Digitalis Glycosides; Diuretics; Female | 1993 |
Death in a patient with primary pulmonary hypertension after 20 mg of nifedipine.
Topics: Adolescent; Cardiac Output; Female; Humans; Hypertension, Pulmonary; Nifedipine; Vasodilation | 1993 |
[Effect of a single dose of nifedipine on pulmonary hypertension measured by doppler echocardiography].
Topics: Aged; Aged, 80 and over; Echocardiography, Doppler; Humans; Hypertension, Pulmonary; Middle Aged; Ni | 1993 |
The effect of nifedipine on monocrotaline-induced pulmonary hypertension in rats.
Topics: Acute Disease; Animals; Body Weight; Disease Models, Animal; Drug Evaluation, Preclinical; Heart Ven | 1993 |
Effects of adenosine in combination with calcium channel blockers in patients with primary pulmonary hypertension.
Topics: Adenosine; Adult; Calcium Channel Blockers; Catheterization, Swan-Ganz; Diltiazem; Drug Therapy, Com | 1993 |
Effects of a combination therapy of anticoagulant and vasodilator on the long-term prognosis of primary pulmonary hypertension.
Topics: Adolescent; Adult; Drug Combinations; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Isoprot | 1993 |
Successful management of labor and delivery in primary pulmonary hypertension.
Topics: Adenosine; Adult; Delivery, Obstetric; Female; Humans; Hypertension, Pulmonary; Nifedipine; Pregnanc | 1993 |
The effect of nifedipine [correction of nifidipine] and cimetidine on the haemodynamics of Egyptian bilharzial pulmonary hypertension.
Topics: Blood Pressure; Cimetidine; Humans; Hypertension, Pulmonary; Nifedipine; Random Allocation; Schistos | 1993 |
Serum nifedipine concentrations and response of patients with pulmonary hypertension.
Topics: Adult; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Nifedipine; Vasodil | 1996 |
Pulmonary oedema and pleural effusion in two patients with primary pulmonary hypertension treated with calcium channel blockers.
Topics: Calcium Channel Blockers; Female; Humans; Hypertension, Pulmonary; Lung; Male; Middle Aged; Nifedipi | 1996 |
Nitric oxide and prostacyclin as test agents of vasoreactivity in severe precapillary pulmonary hypertension: predictive ability and consequences on haemodynamics and gas exchange.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Epoprostenol; Hemodynamics; Humans; Hypertension, | 1997 |
Pharmacologic modulation of pulmonary vascular permeability during air embolism.
Topics: Animals; Capillary Permeability; Cyclooxygenase Inhibitors; Hypertension, Pulmonary; Indomethacin; I | 1997 |
[Effect of calcium channel antagonists in primary pulmonary hypertension in association with human immunodeficiency virus infection].
Topics: Adult; Calcium Channel Blockers; HIV Infections; Humans; Hypertension, Pulmonary; Nifedipine | 1998 |
Rapid recurrence of pulmonary hypertension following cessation of nifedipine.
Topics: Adult; Female; Humans; Hypertension, Pulmonary; Nifedipine; Recurrence; Vasodilator Agents | 1998 |
Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension.
Topics: Administration, Inhalation; Administration, Oral; Calcium Channel Blockers; Diltiazem; Dose-Response | 1998 |
Inhaled nitric oxide and heparin for infantile primary pulmonary hypertension.
Topics: Drug Therapy, Combination; Heparin; Humans; Hypertension, Pulmonary; Infant; Neovascularization, Phy | 1998 |
Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine.
Topics: Administration, Inhalation; Administration, Oral; Calcium Channel Blockers; Female; Hemodynamics; Hu | 1998 |
Pulmonary hypertension in high-altitude chronic hypoxia: response to nifedipine.
Topics: Adolescent; Adult; Altitude; Blood Pressure; Calcium Channel Blockers; Echocardiography, Doppler; Fe | 1998 |
Pulmonary hypertension in pregnancy: treatment with pulmonary vasodilators.
Topics: Adult; Antihypertensive Agents; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Nifedipine; P | 1999 |
Transient left ventricular failure following bilateral lung transplantation for pulmonary hypertension.
Topics: Adult; Alprostadil; Antihypertensive Agents; Cardiac Output, Low; Cardiotonic Agents; Catheterizatio | 1999 |
Nifedipine inhibits pulmonary hypertension but does not prevent decreased lung eNOS in hypoxic newborn pigs.
Topics: Acetylcholine; Animals; Animals, Newborn; Blood Pressure; Calcium Channel Blockers; Hypertension, Pu | 1999 |
Inhaled nitric oxide and nifedipine have similar effects on lung cGMP levels in rats.
Topics: 6-Ketoprostaglandin F1 alpha; Administration, Inhalation; Animals; Bronchodilator Agents; Cyclic AMP | 1999 |
Comparison of the effects of nitric oxide, nitroprusside, and nifedipine on hemodynamics and right ventricular contractility in patients with chronic pulmonary hypertension.
Topics: Administration, Inhalation; Administration, Sublingual; Adult; Aged; Female; Hemodynamics; Humans; H | 2001 |
Upregulated TRP and enhanced capacitative Ca(2+) entry in human pulmonary artery myocytes during proliferation.
Topics: Blood Proteins; Calcium; Calcium Channel Blockers; Calcium Channels; Calcium Channels, L-Type; Cell | 2001 |
Antiphospholipid syndrome presenting as portopulmonary hypertension.
Topics: Adult; Antiphospholipid Syndrome; Calcium Channel Blockers; Female; Humans; Hypertension, Portal; Hy | 2001 |
Beneficial effects on skeletal muscle of the angiotensin II type 1 receptor blocker irbesartan in experimental heart failure.
Topics: Angiotensin II; Animals; Apoptosis; Biphenyl Compounds; Calcium Channel Blockers; Drug Evaluation, P | 2001 |
Comparative effects of beraprost, a stable analogue of prostacyclin, with PGE(1), nitroglycerin and nifedipine on canine model of vasoconstrictive pulmonary hypertension.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Alprostadil; Animals; Antihypert | 2001 |
Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Epoprostenol; Exercise Test; Female; Follow-Up Studies; Humans | 2001 |
Rapid regression of primary pulmonary hypertension.
Topics: Calcium Channel Blockers; Cardiac Catheterization; Combined Modality Therapy; Echocardiography; Fema | 2001 |
[Short-term effects of Angelica sinensis and nifedipine on chronic obstructive pulmonary disease in patients with pulmonary hypertension].
Topics: Aged; Cardiac Output; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Hemodynamics; Humans | 1992 |
Long-term hemodynamic effects of nifedipine on congenital heart disease with Eisenmenger's mechanism in children.
Topics: Child; Child, Preschool; Down Syndrome; Eisenmenger Complex; Heart Septal Defects; Hemodynamics; Hum | 1992 |
[Analysis of natural history and long-term follow-up of 59 patients with obliterative pulmonary hypertension (OPH)].
Topics: Adolescent; Adult; Child; Child, Preschool; China; Female; Follow-Up Studies; Humans; Hypertension, | 1992 |
Short- and long-term hemodynamic effects of oral nifedipine in patients with pulmonary hypertension secondary to COPD and lung fibrosis. Deleterious effects in patients with restrictive disease.
Topics: Aged; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Lung Diseases, Obstructive; Male; Middl | 1992 |
Comparison of the effects of adenosine and nifedipine in pulmonary hypertension.
Topics: Adenosine; Adult; Blood Pressure; Cardiac Output; Dose-Response Relationship, Drug; Female; Humans; | 1992 |
Successful treatment of acute postoperative pulmonary hypertension with nifedipine.
Topics: Humans; Hypertension, Pulmonary; Infant; Male; Nifedipine; Postoperative Complications; Truncus Arte | 1992 |
Acute and long-term effects of nifedipine on pulmonary and systemic hemodynamics in patients with pulmonary hypertension associated with diffuse systemic sclerosis, the CREST syndrome and mixed connective tissue disease.
Topics: Adult; Blood Pressure; Calcinosis; Cardiac Catheterization; Cardiac Output; Dyspnea; Esophageal Moti | 1991 |
[Verapamil and nifedipine limit hemodynamic changes in pulmonary circulation in rats with hypoxia].
Topics: Animals; Antihypertensive Agents; Blood Pressure; Depression, Chemical; Disease Models, Animal; Hype | 1991 |
[Treatment of primary pulmonary hypertension with high doses of nifedipine controlled by Doppler echocardiography].
Topics: Administration, Oral; Adult; Antihypertensive Agents; Blood Pressure; Drug Monitoring; Echocardiogra | 1991 |
Acute nonhemodynamic pulmonary edema with nifedipine in primary pulmonary hypertension.
Topics: Acute Disease; Adult; Blood Pressure; Humans; Hypertension, Pulmonary; Male; Nifedipine; Pulmonary A | 1991 |
[Pulmonary hemodynamics in patients with hypertension during acute drug tests using obsidan and corinfar].
Topics: Adult; Female; Hemodynamics; Humans; Hypertension; Hypertension, Pulmonary; Male; Middle Aged; Nifed | 1991 |
[Pulsed Doppler echocardiography assessment of acute hemodynamic effects of nifedipine on pulmonary hypertension in chronic obstructive lung disease].
Topics: Administration, Sublingual; Adult; Aged; Blood Pressure; Echocardiography, Doppler; Female; Hemodyna | 1991 |
The treatment of primary pulmonary hypertension.
Topics: Arteritis; Humans; Hypertension, Pulmonary; Lung; Nifedipine; Survival Rate; Vasoconstriction; Vasod | 1991 |
Pharmacokinetics and pharmacodynamics of nifedipine in children with bronchopulmonary dysplasia and pulmonary hypertension.
Topics: Administration, Oral; Bronchopulmonary Dysplasia; Child, Preschool; Diuretics; Female; Hemodynamics; | 1991 |
Decrease in pulmonary artery pressure with slow release nifedipine in Saudi patients with primary pulmonary hypertension.
Topics: Adolescent; Adult; Blood Pressure; Clinical Protocols; Delayed-Action Preparations; Female; Humans; | 1991 |
[Effects of nifedipine on pulmonary hypertension in patients with chronic obstructive pulmonary diseases--a comparison with oxygen administration].
Topics: Administration, Sublingual; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Lung Diseases, Ob | 1991 |
High dose titration of calcium channel blocking agents for primary pulmonary hypertension: guidelines for short-term drug testing.
Topics: Adult; Blood Pressure; Diltiazem; Drug Administration Schedule; Drug Evaluation; Female; Hemodynamic | 1991 |
[Comparative study of acute and chronic effects of nifedipine in patients with secondary pulmonary hypertension].
Topics: Adult; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension, Pulmonary; Male; Middl | 1991 |
Hemodynamic profiles of prostaglandin E1, isoproterenol, prostacyclin, and nifedipine in experimental porcine pulmonary hypertension.
Topics: Alprostadil; Animals; Blood Pressure; Cardiac Output; Epoprostenol; Heart Rate; Hemodynamics; Hypert | 1991 |
Experience with long-term nifedipine therapy in paediatric cardiological patients.
Topics: Adolescent; Child; Child, Preschool; Dose-Response Relationship, Drug; Follow-Up Studies; Heart Defe | 1990 |
The influence of nifedipine (Corinfar) on pulmonary hypertension in chronic obstructive lung disease.
Topics: Adolescent; Adult; Aged; Female; Humans; Hypertension, Pulmonary; Long-Term Care; Lung Diseases, Obs | 1990 |
Differential therapy with calcium antagonists in pulmonary hypertension secondary to COPD. Hemodynamic effects of nifedipine, diltiazem, and verapamil.
Topics: Calcium Channel Blockers; Diltiazem; Exercise Test; Hemodynamics; Humans; Hypertension, Pulmonary; L | 1990 |
Hemodynamic effects of diltiazem during vasoconstrictor pulmonary hypertension in sheep.
Topics: Alprostadil; Animals; Diltiazem; Hemodynamics; Hypertension, Pulmonary; Male; Nifedipine; Sheep; Vas | 1990 |
[A case of primary pulmonary hypertension with high venous thromboxane B2 concentration].
Topics: Adult; Cold Temperature; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Nifedipine; Oxygen Inh | 1990 |
[Evaluation of the effects of vasodilator therapy in primary pulmonary hypertension. Experience in 7 cases].
Topics: Adolescent; Adult; Aged; Biopsy; Blood Pressure; Calcium Channel Blockers; Drug Evaluation; Female; | 1990 |
[Interactions of theophylline and nifedipine].
Topics: Adult; Delayed-Action Preparations; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hy | 1990 |
Nifedipine and prazosin in the management of pulmonary hypertension in CREST syndrome.
Topics: Adult; Drug Therapy, Combination; Esophageal Motility Disorders; Hemodynamics; Humans; Hypertension, | 1990 |
[Hemodynamic effects of nifedipine on pulmonary hypertension secondary to congenital heart disease with shunts].
Topics: Adolescent; Adult; Child; Ductus Arteriosus, Patent; Female; Heart Septal Defects, Ventricular; Hemo | 1990 |
Severe pulmonary hypertension in a patient with Whipple's disease.
Topics: Drug Combinations; Furosemide; Heart Failure; Heart Murmurs; Humans; Hypertension, Pulmonary; Male; | 1985 |
[Nifedipine in primary pulmonary hypertension while waiting for heart-lung transplantation].
Topics: Adult; Female; Heart Transplantation; Heart-Lung Transplantation; Humans; Hypertension, Pulmonary; L | 1989 |
[Primary pulmonary hypertension: physiopathology and critical evaluation of the therapy].
Topics: Blood Pressure; Captopril; Drug Evaluation; Epoprostenol; Humans; Hydralazine; Hypertension, Pulmona | 1989 |
[The effect of calcium antagonists on pulmonary hemodynamics in patients with chronic bronchitis with manifest and latent pulmonary hypertension].
Topics: Adult; Bronchitis; Calcium Channel Blockers; Chronic Disease; Drug Evaluation; Female; Hemodynamics; | 1989 |
[A case of primary pulmonary hypertension with beneficial effect of oral long-acting prostaglandin E1 and nifedipine].
Topics: Administration, Oral; Adult; Alprostadil; Delayed-Action Preparations; Drug Evaluation; Drug Therapy | 1989 |
Oxygen therapy and vasodilator therapy in patients with chronic lung disease: the effects of episodic pulmonary hypertension during sleep and exercise performance.
Topics: Blood Pressure; Chronic Disease; Exercise Test; Hemodynamics; Humans; Hypertension, Pulmonary; Isoso | 1989 |
[Therapeutic effects of nifedipine in pulmonary hypertension secondary to congenital heart disease].
Topics: Adolescent; Adult; Child; Ductus Arteriosus, Patent; Female; Heart Septal Defects, Ventricular; Hemo | 1989 |
Acute effects of oxygen, nifedipine, and diltiazem in patients with cystic fibrosis and mild pulmonary hypertension.
Topics: Adolescent; Adult; Airway Resistance; Cystic Fibrosis; Diltiazem; Female; Hemodynamics; Humans; Hype | 1989 |
Vasodilators and primary pulmonary hypertension. Variability of long-term response.
Topics: Adult; Drug Administration Schedule; Drug Evaluation; Female; Hemodynamics; Humans; Hypertension, Pu | 1989 |
[Value of nifedipine in respiratory failure related to obstructive chronic bronchitis during treatment over 6 months].
Topics: Administration, Sublingual; Drug Administration Schedule; Hemodynamics; Humans; Hypertension, Pulmon | 1989 |
Paradoxical elevation of pulmonary vascular resistance after nifedipine in primary pulmonary hypertension. A case study.
Topics: Administration, Oral; Administration, Sublingual; Female; Humans; Hypertension, Pulmonary; Middle Ag | 1989 |
[Efficacy of nifedipine on refractory hypoxemia associated with diaphragmatic hernia in the newborn infant. Apropos of a case].
Topics: Drug Evaluation; Hernia, Diaphragmatic; Hernias, Diaphragmatic, Congenital; Humans; Hypertension, Pu | 1989 |
Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Age Factors; Blood Pressure; Calcium Channel Blocke | 1986 |
Nifedipine reduces pulmonary pressure and vascular tone during short- but not long-term treatment of pulmonary hypertension in patients with chronic obstructive pulmonary disease.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Exercise Test; Female; Humans; Hypertension, Pulmonary; | 1989 |
Comparative effects of oxygen, nifedipine and ketanserin in hypoxic pulmonary hypertension.
Topics: Adult; Carbon Dioxide; Cardiac Output; Female; Heart Rate; Humans; Hypertension, Pulmonary; Hypoxia; | 1985 |
Nitrendipine attenuates the pulmonary vascular remodeling and right ventricular hypertrophy caused by intermittent hypoxia in rats.
Topics: Animals; Cardiomegaly; Heart Ventricles; Hypertension, Pulmonary; Hypertrophy; Hypoxia; Male; Muscle | 1986 |
[Effects of nifedipine on myocardial contractility and pulmonary hypertension in hypoxic rats].
Topics: Animals; Blood Pressure; Hematocrit; Hemodynamics; Hypertension, Pulmonary; Hypoxia; Male; Myocardia | 1987 |
[A case of pulmonary hypertension associated with liver cirrhosis and hepatoma].
Topics: Carcinoma, Hepatocellular; Humans; Hypertension, Pulmonary; Liver Cirrhosis; Liver Neoplasms; Male; | 1985 |
The effect of nifedipine alone or combined with low dose acetylsalicyclic acid on endotoxin-induced pulmonary hypertension in the piglet.
Topics: Animals; Animals, Newborn; Aspirin; Disease Models, Animal; Drug Combinations; Drug Evaluation, Prec | 1988 |
[Nifedipine in the treatment of chronic cor pulmonale].
Topics: Adult; Aged; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Lactates; Lung Diseases, Obstruc | 1986 |
[Vasodilator therapy in pulmonary hypertension and chronic obstructive lung disease (COPD). Hemodynamic studies exemplified by nifedipine and nitroglycerin].
Topics: Exercise Test; Hemodynamics; Humans; Hypertension, Pulmonary; Long-Term Care; Lung Diseases, Obstruc | 1986 |
[Hemodynamic studies of nifedipine (Adalat) in pulmonary hypertension in childhood].
Topics: Adolescent; Cardiac Catheterization; Child; Child, Preschool; Delayed-Action Preparations; Eisenmeng | 1986 |
[Corrective effect of nitrates and calcium antagonists on hemodynamics and ventilation in chronic bronchitis patients with a syndrome of pulmonary hypertension].
Topics: Bronchitis; Calcium Channel Blockers; Drug Therapy, Combination; Hemodynamics; Humans; Hypertension, | 1987 |
[Primary pulmonary hypertension in childhood: the positive long-term therapeutic effect of nifedipine (Corinfar)].
Topics: Child, Preschool; Female; Humans; Hypertension, Pulmonary; Long-Term Care; Nifedipine; Pulmonary Wed | 1987 |
Effect of posture, hydralazine, and nifedipine on hemodynamics, ventilation, and gas exchange in patients with chronic obstructive pulmonary disease.
Topics: Carbon Dioxide; Carbon Monoxide; Hemodynamics; Humans; Hydralazine; Hypertension, Pulmonary; Lung Di | 1988 |
Hemodynamic effects of nifedipine and oxygen in children with pulmonary hypertension.
Topics: Adolescent; Adult; Child; Child, Preschool; Hemodynamics; Humans; Hypertension, Pulmonary; Infant; N | 1988 |
[Noninvasive methods for assessing the effect of nifedipine on cardiorespiratory function in a patient with cystic fibrosis].
Topics: Adult; Cystic Fibrosis; Humans; Hypertension, Pulmonary; Male; Nifedipine; Pulmonary Heart Disease; | 1988 |
Acute hemodynamic effects of nifedipine in infants with bronchopulmonary dysplasia and pulmonary hypertension.
Topics: Blood Pressure; Bronchopulmonary Dysplasia; Cardiac Catheterization; Cardiac Output; Child, Preschoo | 1988 |
Relationship between oxygen uptake and oxygen delivery in patients with pulmonary hypertension.
Topics: Biological Availability; Calcium Channel Blockers; Hemodynamics; Humans; Hypertension, Pulmonary; Lu | 1988 |
[Effects of nifedipine on pulmonary hypertension in patients with chronic respiratory failure--a comparison with oxygen administration at rest and during exercise].
Topics: Adolescent; Adult; Aged; Chronic Disease; Exercise; Humans; Hypertension, Pulmonary; Male; Middle Ag | 1988 |
[Hypoxic pulmonary hypertension: nifedipine therapy].
Topics: Aged; Drug Evaluation; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Lung Diseases, Obstruc | 1988 |
[Effect of a single dose of nifedipine on hemodynamic parameters of pulmonary circulation and left-ventricular function in patients with hypoxic pulmonary hypertension].
Topics: Administration, Sublingual; Adult; Aged; Female; Heart Ventricles; Hemodynamics; Humans; Hypertensio | 1988 |
Unexplained plexogenic pulmonary arteriopathy: an unusual rapidly progressive case in childhood.
Topics: Child, Preschool; Female; Fibromuscular Dysplasia; Heart Failure; Humans; Hypertension, Pulmonary; M | 1988 |
Hemodynamic profiles of prostaglandin E1, isoproterenol, prostacyclin, and nifedipine in vasoconstrictor pulmonary hypertension in sheep.
Topics: Alprostadil; Animals; Drug Evaluation, Preclinical; Epoprostenol; Hemodynamics; Hypertension, Pulmon | 1988 |
Prediction of favourable responses to long term vasodilator treatment of pulmonary hypertension by short term administration of epoprostenol (prostacyclin) or nifedipine.
Topics: Administration, Oral; Administration, Sublingual; Adult; Dose-Response Relationship, Drug; Drug Admi | 1988 |
Value and limitations of calcium channel blockade in the treatment of pulmonary hypertension associated with CREST--case reports.
Topics: Adult; Calcinosis; Diltiazem; Esophageal Diseases; Female; Humans; Hypertension, Pulmonary; Male; Mi | 1988 |
[Effectiveness of calcium antagonists in the treatment of patients with chronic nonspecific lung diseases].
Topics: Adult; Aged; Aminophylline; Calcium Channel Blockers; Chronic Disease; Cinnarizine; Drug Evaluation; | 1988 |
[Effect of the calcium antagonist nifedipine on central and peripheral hemodynamics in patients with primary pulmonary hypertension].
Topics: Adolescent; Adult; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Nifedipine; Pulmonar | 1988 |
Acute haemodynamic effects of nifedipine in patients with ventricular septal defect.
Topics: Adolescent; Blood Pressure; Child; Female; Heart Rate; Heart Septal Defects, Ventricular; Hemodynami | 1988 |
[Noninvasive evaluation of the effectiveness of the treatment of primary pulmonary hypertension. Case report].
Topics: Adult; Blood Pressure; Echocardiography; Female; Humans; Hypertension, Pulmonary; Nifedipine; Pregna | 1987 |
Acute and long term effect of nifedipine on pulmonary hypertension secondary to chronic obstructive airways disease.
Topics: Aged; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Lung Diseases, Obstructive; Male; Middl | 1986 |
Thromboxane synthetase inhibition in primary pulmonary hypertension.
Topics: Adult; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Imidazoles; Male; Middle Aged; Nifedip | 1987 |
[Pulmonary involvement in progressive systemic sclerosis].
Topics: Humans; Hypertension, Pulmonary; Lung Diseases; Nifedipine; Penicillamine; Pulmonary Fibrosis; Scler | 1986 |
[Nifedipine in the treatment of pulmonary hypertension. II--Hypoxic pulmonary hypertension].
Topics: Animals; Humans; Hypertension, Pulmonary; Hypoxia; Nifedipine; Pulmonary Artery; Rats; Vascular Resi | 1986 |
Vasodilators in primary pulmonary hypertension: an old dilemma revisited.
Topics: Adult; Female; Humans; Hypertension, Pulmonary; Male; Nifedipine | 1987 |
Hemodynamic and oxygen delivery responses to nifedipine in pulmonary hypertension secondary to chronic obstructive lung disease.
Topics: Adult; Aged; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Lung Diseases, Obstructive; Male | 1987 |
The value of right atrial emptying rate in predicting reduction in pulmonary artery pressure in patients with chronic obstructive pulmonary disease.
Topics: Blood Pressure; Female; Heart; Heart Atria; Humans; Hypertension, Pulmonary; Lung Diseases, Obstruct | 1987 |
Nifedipine in pulmonary arterial hypertension. Importance of Raynaud's phenomenon.
Topics: Female; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Nifedipine; Pulmonary Wedg | 1987 |
Prostaglandin E1 as a screening vasodilator in primary pulmonary hypertension.
Topics: Adult; Aged; Alprostadil; Female; Hemodynamics; Humans; Hydralazine; Hypertension, Pulmonary; Male; | 1987 |
[Effects of nifedipine on pulmonary circulation in patients with chronic cor pulmonale].
Topics: Adolescent; Adult; Aged; Cardiac Output; Chronic Disease; Female; Humans; Hypertension, Pulmonary; M | 1987 |
[Hemodynamic evaluation of nifedipine in primary pulmonary hypertension--short and long term effects].
Topics: Adult; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Middle Aged; Nifedipine | 1986 |
Long-term treatment with a new calcium antagonist, felodipine, in chronic obstructive lung disease.
Topics: Calcium Channel Blockers; Dose-Response Relationship, Drug; Exercise Test; Felodipine; Humans; Hyper | 1986 |
Strategy to manage pump failure due to chronic pulmonary diseases--pathophysiology and treatment of right ventricular overload.
Topics: Alprostadil; Echocardiography; Heart; Heart Diseases; Heart Ventricles; Humans; Hypertension, Pulmon | 1986 |
Pulmonary vascular responsiveness at rest and during exercise in idiopathic pulmonary fibrosis: effects of oxygen and nifedipine.
Topics: Adult; Blood Pressure; Exercise Test; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Ni | 1986 |
Nifedipine in the treatment of a child with pulmonary hypertension associated with severe bronchopulmonary dysplasia.
Topics: Bronchopulmonary Dysplasia; Hemodynamics; Humans; Hypertension, Pulmonary; Infant; Infant, Newborn; | 1986 |
Severe pulmonary hypertension in a patient with rheumatoid arthritis--response to nifedipine.
Topics: Arthritis, Rheumatoid; Blood Pressure; Humans; Hypertension, Pulmonary; Male; Middle Aged; Nifedipin | 1986 |
Use of continuous-wave Doppler ultrasound to evaluate and manage primary pulmonary hypertension.
Topics: Adult; Blood Pressure; Echocardiography; Female; Humans; Hypertension, Pulmonary; Nifedipine | 1986 |
[Remote results of the successful treatment with nifedipine of 2 patients with primary pulmonary hypertension].
Topics: Adolescent; Adult; Blood Pressure; Female; Humans; Hypertension, Pulmonary; Nifedipine; Pulmonary Ar | 1986 |
[Primary pulmonary hypertension. A critical review of the literature and presentation of a case].
Topics: Aged; Electrocardiography; Female; Humans; Hypertension, Pulmonary; Nifedipine | 1986 |
[Hemodynamic and gas exchange effects of nifedipine in patients with chronic pulmonary disease].
Topics: Female; Hemodynamics; Hypertension, Pulmonary; Lung Diseases; Male; Nifedipine; Pulmonary Gas Exchan | 1986 |
[Effects of oxygen and nifedipine on hemodynamics in secondary pulmonary hypertension--chronic pulmonary emphysema and chronic lung tuberculosis].
Topics: Chronic Disease; Hemodynamics; Humans; Hypertension, Pulmonary; Nifedipine; Oxygen; Oxygen Consumpti | 1986 |
Long-term favourable effect of nifedipine in primary pulmonary hypertension. Report of a case with hemodynamic evaluation after 3 and after 16 months and with clinical follow-up during 36 months.
Topics: Adult; Cardiac Catheterization; Female; Follow-Up Studies; Hemodynamics; Humans; Hypertension, Pulmo | 1985 |
Comparative effects of nisoldipine, nifedipine and bepridil on experimental pulmonary hypertension.
Topics: Animals; Bepridil; Blood Gas Analysis; Calcium Channel Blockers; Dinoprost; Dogs; Female; Hemodynami | 1985 |
Hemodynamic effects of nifedipine on secondary pulmonary hypertension in man.
Topics: Blood Pressure; Cardiac Output; Hemodynamics; Humans; Hypertension, Pulmonary; Nifedipine; Oxygen; P | 1985 |
Noninvasive assessment of hemodynamic improvement during chronic vasodilator therapy in obliterative pulmonary hypertension.
Topics: Adult; Animals; Cardiac Catheterization; Diltiazem; Exercise Test; Female; Hemodynamics; Humans; Hyp | 1986 |
Magnitude and implications of spontaneous hemodynamic variability in primary pulmonary hypertension.
Topics: Adult; Blood Pressure; Cardiac Output; Female; Hemodynamics; Humans; Hydralazine; Hypertension, Pulm | 1985 |
Hypotension and sinus arrest with nifedipine in pulmonary hypertension.
Topics: Arrhythmia, Sinus; Female; Humans; Hypertension, Pulmonary; Hypotension; Middle Aged; Nifedipine | 1985 |
[Immediate effects of nifedipine and oxygen in acute episodes of chronic cor pulmonale].
Topics: Adult; Aged; Humans; Hypertension, Pulmonary; Lung Diseases, Obstructive; Middle Aged; Nifedipine; O | 1985 |
Hemodynamic effects of nifedipine in normoxic and hypoxic newborn lambs.
Topics: Analysis of Variance; Animals; Animals, Newborn; Blood Gas Analysis; Blood Pressure; Disease Models, | 1985 |
The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension.
Topics: Adolescent; Adult; Child; Female; Hemodynamics; Humans; Hydralazine; Hypertension, Pulmonary; Male; | 1985 |
Pulmonary edema with nifedipine in primary pulmonary hypertension.
Topics: Adult; Female; Humans; Hypertension, Pulmonary; Nifedipine; Pulmonary Edema | 1985 |
Pulmonary hypertension in systemic lupus erythematosus.
Topics: Adult; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hydralazine; Hypertension, Pulmona | 1985 |
Calcium channel blockers in primary pulmonary hypertension.
Topics: Calcium Channel Blockers; Diltiazem; Humans; Hypertension, Pulmonary; Nifedipine; Verapamil | 1985 |
The role of vasodilators in patients with progressive systemic sclerosis. Interstitial lung disease and pulmonary hypertension.
Topics: Humans; Hydralazine; Hypertension, Pulmonary; Lung Diseases; Nifedipine; Pulmonary Fibrosis; Sarcoid | 1985 |
Nifedipine dilates the pulmonary vasculature without producing symptomatic systemic hypotension in upright resting and exercising patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease.
Topics: Adult; Blood Pressure; Female; Humans; Hypertension, Pulmonary; Hypotension; Lung Diseases, Obstruct | 1985 |
[Variable hemodynamic response to nifedipine in pulmonary hypertension secondary to chronic obstructive bronchopathy and pulmonary fibrosis].
Topics: Blood Pressure; Cardiac Output; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Lung Diseases | 1985 |
The effect of a new calcium antagonist, felodipine, on pulmonary hypertension and gas exchange in chronic obstructive lung disease.
Topics: Adult; Aged; Calcium Channel Blockers; Dose-Response Relationship, Drug; Felodipine; Female; Hemodyn | 1985 |
Two-week nifedipine treatment for pulmonary hypertension complicating chronic obstructive lung disease.
Topics: Administration, Oral; Aged; Cardiac Output; Humans; Hypertension, Pulmonary; Lung Diseases, Obstruct | 1985 |
[Vasodilator therapy in chronic thromboembolic cor pulmonare. Description of a case with unfavorable hemodynamic effects].
Topics: Adult; Female; Heart Block; Humans; Hypertension, Pulmonary; Hypotension; Nifedipine; Pulmonary Embo | 1985 |
Transient effect of nifedipine on pulmonary hypertension of systemic sclerosis.
Topics: Female; Hemodynamics; Humans; Hypertension, Pulmonary; Middle Aged; Nifedipine; Scleroderma, Systemi | 1985 |